Chromosome	Start	End	Width	SNPs	Minimal p-value	Disease/Trait	SNP(p-value,Pubmed ID)
chr1	4295141	4378141	83001	rs966321	8e-06	Factor VII	rs966321 (8e-06,17903294)
chr1	5101141	5322141	221001	rs7513590	5e-06	Anthropometric traits	rs7513590 (5e-06,19260139)
chr1	22649695	22739695	90001	rs111724808;rs34920465;rs12568930;rs6426749;rs7524102;rs6696981	7e-57	PR interval in Tripanosoma cruzi seropositivity;Bone mineral density;Inflammatory bowel disease;Dupuytren's disease;Ulcerative colitis;Bone mineral density (hip);Bone mineral density (spine)	rs111724808 (4e-07,24324551);rs34920465 (3e-13,24249740);rs34920465 (3e-08,24249740);rs12568930 (1e-17,23128233);rs6426749 (7e-57,22504420);rs7524102 (3e-09,21732829);rs7524102 (9e-07,21533022);rs7524102 (1e-06,21533022);rs7524102 (2e-13,21297633);rs7524102 (3e-07,19915572);rs6426749 (9e-08,19801982);rs7524102 (3e-10,19801982);rs7524102 (1e-16,19079262);rs6696981 (2e-08,19079262);rs7524102 (5e-16,18445777);rs7524102 (9e-09,18445777)
chr1	30564414	30690414	126001	rs910696;rs2180233	3e-06	Smoking behavior;Attention deficit hyperactivity disorder and conduct disorder	rs910696 (3e-06,19247474);rs2180233 (9e-06,18951430)
chr1	55790980	56416980	626001	rs10443215;rs1165472;rs1998013;rs6684428;rs72669744;rs10888935	1e-19	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);Paclitaxel-induced neuropathy;Metabolite levels;Airflow obstruction ;Lipid metabolism phenotypes;Inflammatory biomarkers	rs10443215 (9e-06,24025145);rs1165472 (4e-06,23776197);rs1998013 (5e-13,22916037);rs6684428 (5e-07,22837378);rs72669744 (1e-19,22286219);rs10888935 (7e-07,22228203)
chr1	60949605	61137980	188376	rs12565755;rs2989476;rs472913	5e-08	Response to tocilizumab in rheumatoid arthritis;Bipolar disorder	rs12565755 (5e-08,22491018);rs2989476 (3e-06,21738484);rs2989476 (2e-06,21254220);rs472913 (2e-07,19416921)
chr1	67734481	67764597	30117	rs1495965;rs924080	2e-11	Behcet's disease	rs1495965 (2e-11,20622879);rs924080 (7e-09,20622878)
chr1	69381413	69731413	350001	rs4147141;rs4650135	5e-06	Attention deficit hyperactivity disorder;Inattentive symptoms	rs4147141 (6e-06,18821565);rs4147141 (8e-06,18821565);rs4650135 (5e-06,18821565)
chr1	79186202	79264980	78779	rs4650608;rs1937020;rs10873998;rs12730292	8e-09	Schizophrenia or bipolar disorder;Anorexia nervosa;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder	rs4650608 (8e-09,24280982);rs1937020 (4e-06,23568457);rs10873998 (4e-06,23453885);rs4650608 (1e-06,23453885);rs4650608 (8e-09,22182935);rs12730292 (5e-06,21926972)
chr1	80176413	80390413	214001	rs12024204	6e-06	Endometriosis	rs12024204 (6e-06,21151130)
chr1	83234413	83595413	361001	rs12742923;rs11163585	8e-07	HIV-associated dementia ;Response to antipsychotic treatment	rs12742923 (8e-07,22628157);rs11163585 (9e-07,20195266)
chr1	88595413	88928413	333001	rs10923038;rs12032672;rs2179965	4e-07	Serum protein levels (sST2);Periodontal microbiota;Cognitive test performance	rs10923038 (4e-07,23999434);rs12032672 (1e-06,22699663);rs2179965 (1e-06,17903297)
chr1	92036362	92100980	64619	rs1192415	3e-28	Optic disc parameters;Optic nerve measurement (disc area)	rs1192415 (8e-17,21307088);rs1192415 (3e-28,20548946);rs1192415 (3e-07,20395239)
chr1	95020980	95076980	56001	rs1146509;rs2022309;rs7542900;rs12029080	6e-52	QRS duration in Tripanosoma cruzi seropositivity;End-stage coagulation;Type 2 diabetes;D-dimer levels	rs1146509 (6e-06,24324551);rs2022309 (4e-08,23381943);rs7542900 (6e-06,22238593);rs12029080 (6e-52,21502573)
chr1	106966959	107434959	468001	rs12097821;rs12726652	6e-10	Non-obstructive azoospermia;Response to antipsychotic treatment in schizophrenia (working memory)	rs12097821 (6e-10,22197933);rs12726652 (5e-07,21107309)
chr1	110331959	110439959	108001	rs6537883;rs333960;rs10494112;rs484959	7e-35	Sensory disturbances after bilateral sagittal split ramus osteotomy;Obesity-related traits;Paget's disease	rs6537883 (3e-06,23834954);rs333960 (2e-07,23251661);rs10494112 (7e-35,21623375);rs484959 (5e-24,20436471)
chr1	118749478	118987959	238482	rs2474937;rs7534091;rs7527203;rs9428104;rs17038182;rs12735613	6e-23	Congenital heart malformation;Height;Obesity-related traits	rs2474937 (8e-10,23708190);rs7534091 (2e-16,23563607);rs7527203 (2e-06,23251661);rs9428104 (6e-23,20881960);rs17038182 (5e-07,19396169);rs12735613 (4e-11,18391952)
chr1	154795928	154819358	23431	rs6666258;rs13376333	2e-21	Atrial fibrillation	rs6666258 (2e-14,22544366);rs13376333 (2e-21,20173747)
chr1	156867928	156871928	4001	rs12566888	5e-19	Platelet aggregation	rs12566888 (4e-16,20526338);rs12566888 (5e-19,20526338)
chr1	162128343	162252869	124527	rs4657175;rs12029454;rs4657178	3e-45	QT interval	rs4657175 (1e-09,22726844);rs12029454 (3e-45,19305408);rs4657178 (7e-33,19305409)
chr1	168602861	168624343	21483	rs1412337	2e-09	Morbidity-free survival	rs1412337 (2e-09,17903295)
chr1	172801344	172936344	135001	rs9286879;rs7517810;rs12035082	6e-22	Crohn's disease	rs9286879 (6e-22,23128233);rs7517810 (2e-15,21102463);rs9286879 (2e-09,18587394);rs12035082 (2e-07,17554261)
chr1	191428344	191759597	331254	rs10801047	3e-08	Crohn's disease	rs10801047 (3e-08,17554261)
chr1	218812606	218862606	50001	rs993925	1e-08	Pulmonary function	rs993925 (1e-08,21946350)
chr1	219622595	219798631	176037	rs994767;rs2820443;rs2820464;rs1417066;rs2785980;rs11118316;rs12022722;rs3001032;rs2791553;rs11118346;rs2605100	7e-16	Axial length;Sexual dimorphism in anthropometric traits;Waist-hip ratio;Osteoarthritis;Fasting insulin-related traits (interaction with BMI);Visceral adipose tissue/subcutaneous adipose tissue ratio;Adiponectin levels;Height;Adiposity	rs994767 (1e-11,24144296);rs2820443 (7e-16,23754948);rs2820464 (7e-09,23563607);rs1417066 (1e-06,22763110);rs2785980 (2e-08,22581228);rs11118316 (3e-09,22589738);rs12022722 (2e-06,22589738);rs3001032 (4e-08,22479202);rs2791553 (5e-07,22479202);rs11118346 (2e-12,20881960);rs2605100 (3e-08,19557161)
chr1	222010865	222073606	62742	rs6691170	1e-09	Colorectal cancer	rs6691170 (1e-09,20972440)
chr1	222075606	222281874	206269	rs10863681;rs6687758;rs873549	6e-23	Metabolite levels (HVA-5-HIAA Factor score);Progressive supranuclear palsy;Colorectal cancer;Keloid	rs10863681 (6e-06,23319000);rs6687758 (6e-08,21685912);rs6687758 (2e-09,20972440);rs873549 (6e-23,20711176)
chr1	228943743	229034643	90901	rs11585386;rs801112;rs801114	6e-12	Aging;Endometriosis;Basal cell carcinoma 	rs11585386 (5e-06,22773346);rs801112 (5e-06,20844546);rs801114 (6e-12,18849993)
chr1	234840802	234880266	39465	rs514230	5e-14	Cholesterol, total;LDL cholesterol	rs514230 (5e-14,24097068);rs514230 (9e-12,24097068);rs514230 (5e-14,20686565);rs514230 (9e-12,20686565)
chr10	3484001	3713001	229001	rs7092929;rs705469;rs705471;rs2165468	3e-07	Coronary artery calcification;Capecitabine sensitivity;Bone mineral density	rs7092929 (3e-07,23870195);rs705469 (7e-06,22864933);rs705471 (7e-06,22864933);rs2165468 (1e-06,17903296)
chr10	4612001	4668001	56001	rs10458787	1e-06	Body mass index	rs10458787 (1e-06,20397748)
chr10	6575952	6621995	46044	rs4748153	3e-08	Immune response to smallpox vaccine (IL-6)	rs4748153 (3e-08,22542470)
chr10	8685995	8776995	91001	rs827382;rs10795668	3e-13	Migraine;Colorectal cancer	rs827382 (9e-08,23793025);rs10795668 (3e-13,18372905)
chr10	8923995	9039995	116001	rs2388896;rs10508372	2e-15	Tetralogy of Fallot;Asthma	rs2388896 (9e-08,23297363);rs10508372 (2e-15,21804548)
chr10	18349995	18418995	69001	rs10508558;rs17661538	1e-06	Bipolar disorder and schizophrenia;Response to antipsychotic treatment	rs10508558 (9e-06,20889312);rs17661538 (1e-06,20195266)
chr10	20773995	20913995	140001	rs11012167;rs7897194;rs2359536;rs16920624	7e-07	QRS duration in Tripanosoma cruzi seropositivity;Bipolar disorder;Peripheral artery disease;Response to antidepressants	rs11012167 (6e-06,24324551);rs7897194 (8e-06,22925353);rs2359536 (2e-06,20610895);rs16920624 (7e-07,20360315)
chr10	29276995	29315995	39001	rs11007350;rs1612122	3e-06	Cannabis dependence;Major depressive disorder (broad)	rs11007350 (3e-06,21668797);rs1612122 (7e-06,20038947)
chr10	31289995	31479995	190001	rs793108;rs2994684	1e-09	Rheumatoid arthritis;Multiple sclerosis;Response to antipsychotic treatment	rs793108 (1e-09,24390342);rs793108 (6e-07,24390342);rs793108 (3e-06,21833088);rs2994684 (3e-07,20195266)
chr10	43796995	43818995	22001	rs2503875	2e-07	Multiple sclerosis	rs2503875 (2e-07,20598377)
chr10	45141995	45247995	106001	rs1480597	2e-06	Parkinson's disease	rs1480597 (2e-06,17052657)
chr10	54157995	54237995	80001	rs1733724	3e-08	QRS duration;Electrocardiographic traits	rs1733724 (3e-08,21076409);rs1733724 (7e-08,20062063)
chr10	54409995	54442995	33001	rs1373004	2e-12	Bone mineral density	rs1373004 (2e-12,22504420)
chr10	55248995	55540995	292001	rs7077606;rs12256830;rs583012	2e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;Immune response to smallpox vaccine (IL-6);Select biomarker traits	rs7077606 (5e-07,23400010);rs12256830 (2e-10,22542470);rs583012 (2e-06,17903293)
chr10	59158995	59290995	132001	rs4462262	9e-08	Diabetic retinopathy 	rs4462262 (9e-08,21310492)
chr10	64438485	64551995	113511	rs10761659;rs10995271;rs224136	6e-46	Inflammatory bowel disease;Crohn's disease	rs10761659 (6e-46,23128233);rs10761659 (5e-06,22936669);rs10761659 (4e-22,21102463);rs10995271 (4e-20,18587394);rs10761659 (2e-06,17554300);rs224136 (1e-10,17435756)
chr10	80093995	80224995	131001	rs2395528	6e-06	Conduct disorder (interaction)	rs2395528 (6e-06,18846501)
chr10	107418011	107672011	254001	rs17119461	7e-12	Melanoma	rs17119461 (7e-12,21706340)
chr10	112869729	112923370	53642	rs2065779;rs869244	3e-12	Insomnia (caffeine-induced);Platelet aggregation	rs2065779 (3e-06,22754043);rs869244 (3e-12,20526338)
chr10	112967011	113044229	77219	rs10885122	3e-16	Fasting glucose-related traits (interaction with BMI);Fasting glucose-related traits	rs10885122 (9e-08,22581228);rs10885122 (3e-16,20081858);rs10885122 (2e-06,20081858)
chr10	115779011	115783011	4001	rs2782980	2e-09	Blood pressure	rs2782980 (2e-09,21909110)
chr10	119349011	119421011	72001	rs181654;rs2184898	1e-07	Airflow obstruction ;Conduct disorder	rs181654 (1e-07,22837378);rs2184898 (3e-06,20585324)
chr10	120252854	120338836	85983	rs12413624	5e-11	Pancreatic cancer	rs12413624 (5e-11,22158540)
chr10	123002805	123093011	90207	rs11199874;rs10788160	5e-15	Prostate cancer;Serum prostate-specific antigen levels	rs11199874 (3e-10,22130093);rs10788160 (5e-15,21160077)
chr10	130064011	130165011	101001	rs11818629	3e-06	HIV-1 control	rs11818629 (3e-06,20041166)
chr10	133150011	133204011	54001	rs10734105	3e-08	Crohn's disease	rs10734105 (3e-08,22412388)
chr11	2685425	2737904	52480	rs231362	3e-13	Type 2 diabetes	rs231362 (3e-13,20581827)
chr11	2818425	2863425	45001	rs2237897;rs8181588;rs2237892;rs163182;rs2237895	2e-42	Type 2 diabetes	rs2237897 (9e-15,24390345);rs8181588 (5e-09,24101674);rs2237892 (4e-29,23945395);rs2237892 (1e-07,22961080);rs163182 (2e-17,21799836);rs2237892 (4e-06,21573907);rs2237895 (1e-09,20174558);rs2237892 (1e-26,19401414);rs2237897 (1e-16,18711366);rs2237892 (2e-42,18711367)
chr11	10370425	10416427	46003	rs2923084;rs6484218	4e-08	HDL cholesterol;Schizophrenia, bipolar disorder and depression (combined)	rs2923084 (5e-08,24097068);rs6484218 (4e-08,20713499);rs2923084 (5e-08,20686565)
chr11	15624425	15744425	120001	rs7108738;rs7117858	1e-32	Bone mineral density;Bone mineral density (hip)	rs7108738 (1e-15,24249740);rs7108738 (1e-32,22504420);rs7117858 (6e-10,19801982)
chr11	15918425	15980959	62535	rs11023787	5e-06	Bone mineral density (wrist)	rs11023787 (5e-06,21104366)
chr11	19569425	19598425	29001	rs10500856;rs874426	4e-06	Obesity-related traits;Attention deficit hyperactivity disorder (time to onset)	rs10500856 (7e-06,23251661);rs874426 (4e-06,18937294)
chr11	22923425	23114425	191001	rs10833905	7e-07	Sudden cardiac arrest	rs10833905 (7e-07,21658281)
chr11	28743425	29292425	549001	rs1491818;rs1602565	3e-06	Amyotrophic lateral sclerosis (age of onset);Schizophrenia	rs1491818 (8e-06,22959728);rs1602565 (3e-06,18677311)
chr11	30748425	30776951	28527	rs10767873;rs963837;rs3925584	8e-18	Renal function-related traits (BUN);Renal function-related traits (eGRFcrea);Renal function-related traits (sCR);Chronic kidney disease;Magnesium levels	rs10767873 (5e-16,22797727);rs963837 (1e-09,22797727);rs963837 (3e-09,22797727);rs3925584 (8e-18,22479191);rs3925584 (5e-16,20700443)
chr11	32296108	32388501	92394	rs2057178	1e-12	Tuberculosis	rs2057178 (3e-06,24057671);rs2057178 (1e-12,24057671);rs2057178 (3e-11,22306650)
chr11	34766425	34860425	94001	rs7929679;rs12793173	1e-09	Chronic obstructive pulmonary disease-related biomarkers;Cystic fibrosis severity	rs7929679 (7e-09,23144326);rs12793173 (1e-09,21602797)
chr11	40831425	40887425	56001	rs78015633;rs4611189	6e-07	PR interval in Tripanosoma cruzi seropositivity;Response to antipsychotic treatment in schizophrenia (reasoning)	rs78015633 (9e-06,24324551);rs4611189 (6e-07,21107309)
chr11	41752425	42244425	492001	rs1484948;rs9300039	6e-08	RR interval (heart rate);Type 2 diabetes	rs1484948 (2e-06,20031603);rs9300039 (6e-08,17463248)
chr11	68963425	69037075	73651	rs7130881;rs11228565;rs7931342;rs10896449	8e-13	Prostate cancer	rs7130881 (9e-09,21743057);rs7130881 (8e-13,19767753);rs11228565 (7e-12,19767754);rs7931342 (2e-12,18264097);rs10896449 (2e-09,18264096)
chr11	69228820	69342820	114001	rs614367;rs4980785;rs7105934	2e-63	Breast cancer;Renal cell carcinoma	rs614367 (2e-63,23535729);rs4980785 (2e-06,22010048);rs7105934 (8e-14,21131975);rs614367 (3e-15,20453838)
chr11	76266353	76340353	74001	rs7130588;rs2155219;rs11236809;rs7927997;rs7927894	4e-36	Atopic dermatitis;Allergic sensitization;Self-reported allergy;Inflammatory bowel disease;Allergic rhinitis;IgE grass sensitization;Asthma;Ulcerative colitis;Crohn's disease	rs7130588 (4e-13,23886662);rs2155219 (1e-18,23817571);rs2155219 (2e-19,23817569);rs2155219 (4e-36,23128233);rs11236809 (3e-06,23042114);rs2155219 (4e-08,22036096);rs2155219 (1e-08,22036096);rs7130588 (2e-08,21907864);rs2155219 (5e-16,21297633);rs7927997 (6e-13,21102463);rs7927894 (8e-10,19349984);rs7927894 (1e-09,18587394)
chr11	79055353	79208353	153001	rs12576775;rs12290811;rs530965	4e-08	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;Cognitive test performance	rs12576775 (4e-08,23453885);rs12576775 (4e-08,21926972);rs12290811 (4e-06,18711365);rs530965 (4e-06,17903297)
chr11	80800353	80857353	57001	rs1357339	5e-06	HIV-1 viral setpoint	rs1357339 (5e-06,20205591)
chr11	90786353	90954353	168001	rs1528753	8e-08	Aging traits	rs1528753 (8e-08,17903295)
chr11	91946353	91974353	28001	rs1350445	9e-06	Subclinical atherosclerosis traits (other)	rs1350445 (9e-06,17903303)
chr11	95268353	95342353	74001	rs4409785	2e-13	Rheumatoid arthritis;Vitiligo;Multiple sclerosis	rs4409785 (1e-11,24390342);rs4409785 (4e-09,24390342);rs4409785 (2e-13,22561518);rs4409785 (6e-07,21833088)
chr11	95858353	95981353	123001	rs10765792	8e-13	Sudden cardiac arrest	rs10765792 (8e-13,21658281)
chr11	98431791	98704791	273001	rs4237591	2e-06	Non-alcoholic fatty liver disease histology (lobular)	rs4237591 (2e-06,20708005)
chr11	103547279	103761177	213899	rs1917445;rs974819	2e-09	Neutrophil count;Coronary heart disease	rs1917445 (6e-07,21507922);rs974819 (2e-09,21378988)
chr11	104227515	104585713	358199	rs11226373	2e-18	Matrix metalloproteinase levels	rs11226373 (2e-18,20031604)
chr11	106252791	106402791	150001	rs10895959	3e-06	Inattentive symptoms	rs10895959 (3e-06,18821565)
chr11	112349791	112458791	109001	rs7105881	3e-07	Response to antipsychotic treatment	rs7105881 (3e-07,20195266)
chr11	115614791	115769791	155001	rs638882	4e-06	Hip geometry	rs638882 (4e-06,17903296)
chr11	116277791	116300791	23001	rs490592	1e-06	Brain structure	rs490592 (1e-06,20171287)
chr11	122087791	122198791	111001	rs565229	4e-06	Hemostatic factors and hematological phenotypes	rs565229 (4e-06,17903294)
chr11	122868204	122884791	16588	rs2126200;rs6589964	2e-12	IgG glycosylation;Menarche (age at onset)	rs2126200 (7e-06,23382691);rs6589964 (2e-12,21102462)
chr11	124599791	124609368	9578	rs12807809	2e-09	Schizophrenia	rs12807809 (2e-09,19571808)
chr11	127586791	127902791	316001	rs7927044	7e-09	Asthma (childhood onset)	rs7927044 (7e-09,22560479)
chr11	128188791	128240791	52001	rs4937314;rs6590322	7e-06	Alzheimer's disease (late onset);Hippocampal atrophy	rs4937314 (7e-06,22881374);rs6590322 (9e-06,19668339)
chr12	2270740	2440463	169724	rs1006737;rs4765905;rs4765913	6e-13	Schizophrenia or bipolar disorder;Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;Bipolar disorder and major depressive disorder (combined)	rs1006737 (6e-13,24280982);rs1006737 (7e-08,24280982);rs1006737 (2e-06,24280982);rs1006737 (5e-12,23974872);rs1006737 (5e-09,23453885);rs4765905 (1e-07,22688191);rs4765905 (2e-07,22688191);rs4765905 (2e-06,21926974);rs4765913 (2e-08,21926972);rs1006737 (3e-08,20351715);rs1006737 (7e-08,18711365)
chr12	4318740	4341537	22798	rs10849023;rs11611647	8e-12	Red blood cell traits;Red blood cell count	rs10849023 (8e-12,23222517);rs11611647 (6e-09,20139978)
chr12	20142734	20288734	146001	rs10770612	2e-08	Aortic root size	rs10770612 (2e-08,19584346)
chr12	20378734	20476734	98001	rs7134375	1e-08	HDL cholesterol	rs7134375 (1e-08,24097068);rs7134375 (4e-08,20686565)
chr12	24155874	24271549	115676	rs10842262	2e-09	Non-obstructive azoospermia	rs10842262 (2e-09,22197933)
chr12	24750734	24834734	84001	rs17287293;rs11047543	3e-20	Heart rate;Resting heart rate;PR interval	rs17287293 (3e-20,23583979);rs17287293 (2e-10,20639392);rs11047543 (3e-13,20062060)
chr12	27980734	28049128	68395	rs258401;rs7953528	2e-12	Retinopathy in non-diabetics;Bone mineral density	rs258401 (6e-06,23393555);rs7953528 (2e-12,22504420)
chr12	30103734	30119734	16001	rs2046383;rs1463605	7e-08	Heart failure;Aging traits	rs2046383 (3e-06,20445134);rs1463605 (7e-08,17903295)
chr12	42118734	42283734	165001	rs871392	3e-06	Biochemical measures	rs871392 (3e-06,19260141)
chr12	43093734	43211734	118001	rs12316797;rs2731006	1e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio;Panic disorder	rs12316797 (1e-06,22589738);rs2731006 (4e-06,19165232)
chr12	66117734	66162734	45001	rs10784496	3e-07	Cerebrospinal AB1-42 levels	rs10784496 (3e-07,20932310)
chr12	66390734	66425734	35001	rs4026608	2e-09	Aortic root size	rs4026608 (2e-09,19584346)
chr12	68469278	68508352	39075	rs7134599;rs1558744	9e-32	Inflammatory bowel disease;Ulcerative colitis	rs7134599 (9e-32,23128233);rs7134599 (1e-16,21297633);rs1558744 (4e-12,20228799);rs1558744 (3e-12,19122664)
chr12	68763734	68793734	30001	rs416350	4e-08	Temperament (bipolar disorder)	rs416350 (4e-08,22365631)
chr12	69824734	69831983	7250	rs10748128;rs11177669	2e-20	Height	rs10748128 (7e-15,23563607);rs10748128 (2e-20,20881960);rs11177669 (3e-06,18391951)
chr12	73764734	74633734	869001	rs7964120;rs7963521;rs10506701;rs1154865	7e-07	Obesity-related traits;Chemerin levels;Bone mineral density;Breast cancer	rs7964120 (5e-06,23251661);rs7963521 (9e-06,20237162);rs10506701 (1e-06,17903296);rs1154865 (7e-07,17903305)
chr12	76197734	76259734	62001	rs7307780	5e-15	Sudden cardiac arrest	rs7307780 (5e-15,21658281)
chr12	77587870	77744870	157001	rs6538140;rs1402279	4e-06	Tuberculosis;Smoking behavior	rs6538140 (4e-06,24057671);rs1402279 (5e-06,19247474)
chr12	84366533	84999533	633001	rs1545843	1e-09	Major depressive disorder	rs1545843 (1e-09,21521612)
chr12	89164082	89342533	178452	rs12821256	4e-30	Hair color;Blond vs. brown hair color	rs12821256 (7e-19,23548203);rs12821256 (4e-30,17952075)
chr12	90150381	90571533	421153	rs7965584;rs10858945;rs10858946	1e-16	Magnesium levels;Optic nerve measurement (cup area);Optic nerve measurement (cup-to-disc ratio)	rs7965584 (1e-16,20700443);rs10858945 (6e-06,20395239);rs10858946 (6e-06,20395239)
chr12	91036870	91161870	125001	rs1847461	8e-06	Smoking behavior	rs1847461 (8e-06,19247474)
chr12	92044870	92305870	261001	rs17019682;rs10777332	2e-06	Heart failure;Biochemical measures	rs17019682 (2e-06,20445134);rs10777332 (5e-06,19260141)
chr12	97662870	97701870	39001	rs10777845	5e-06	Sudden cardiac arrest	rs10777845 (5e-06,21658281)
chr12	102338533	102391632	53100	rs7971536	8e-14	Height	rs7971536 (8e-14,20881960)
chr12	113965618	114027618	62001	rs11066587	5e-06	Quantitative traits	rs11066587 (5e-06,19197348)
chr12	115342281	115385281	43001	rs10850408;rs2384550;rs1896312	3e-17	Alzheimer's disease;Blood pressure;PR interval;Diastolic blood pressure	rs10850408 (9e-07,22159054);rs2384550 (4e-06,21909110);rs1896312 (3e-17,20062060);rs2384550 (4e-08,19430479)
chr12	115446618	115559281	112664	rs35444;rs2194980	1e-10	Blood pressure;Metabolite levels	rs35444 (8e-07,21572416);rs35444 (1e-10,21572416);rs2194980 (3e-07,19043545)
chr12	127761048	127834048	73001	rs1823172;rs10744304	5e-07	Sudden cardiac arrest;Depression (quantitative trait)	rs1823172 (5e-07,21658281);rs10744304 (9e-06,20800221)
chr12	131371048	131397048	26001	rs7299940	7e-06	Panic disorder	rs7299940 (7e-06,19165232)
chr13	22292000	22326000	34001	rs518590	2e-07	Response to antipsychotic treatment	rs518590 (2e-07,20195266)
chr13	22654000	22719000	65001	rs7318731	1e-06	RR interval (heart rate)	rs7318731 (1e-06,20031603)
chr13	23220000	23247227	27228	rs1034200	4e-09	Corneal structure;Central corneal thickness	rs1034200 (4e-09,23291589);rs1034200 (4e-09,20719862)
chr13	24587000	24614000	27001	rs17079773	5e-06	Inattentive symptoms	rs17079773 (5e-06,18821565)
chr13	27395000	27435000	40001	rs9319321	3e-06	Asthma (toluene diisocyanate-induced)	rs9319321 (3e-06,19187332)
chr13	27509000	27565000	56001	rs17085007	3e-19	Ulcerative colitis;Inflammatory bowel disease	rs17085007 (3e-07,23511034);rs17085007 (8e-06,23511034);rs17085007 (3e-19,23128233);rs17085007 (1e-16,21297633);rs17085007 (7e-08,19915573)
chr13	29367000	29436000	69001	rs954108;rs1161463	1e-06	Obesity-related traits;Attention deficit hyperactivity disorder symptoms (interaction)	rs954108 (1e-06,23251661);rs1161463 (2e-06,18846501)
chr13	37997000	38068000	71001	rs9646096;rs1590305	3e-06	Age-related macular degeneration;Hip geometry	rs9646096 (6e-06,23326517);rs1590305 (3e-06,17903296)
chr13	38464000	38634000	170001	rs9548119	9e-06	Self-rated health	rs9548119 (9e-06,20707712)
chr13	40502000	40656000	154001	rs9548988	3e-07	Ulcerative colitis	rs9548988 (3e-07,19915572)
chr13	40747000	40861000	114001	rs10492681	2e-06	Select biomarker traits	rs10492681 (2e-06,17903293)
chr13	41003000	41046000	43001	rs941823	2e-14	Inflammatory bowel disease;Ulcerative colitis	rs941823 (2e-14,23128233);rs941823 (4e-12,21297633)
chr13	42949000	43103000	154001	rs9533095;rs9533090;rs17638544;rs9594738;rs2062305;rs9594759	5e-68	Bone mineral density;Crohn's disease;Bone mineral density (spine);Bone mineral density (hip)	rs9533095 (2e-15,24249740);rs9533090 (3e-07,24249740);rs17638544 (5e-06,23437003);rs9533090 (5e-68,22504420);rs9594738 (4e-06,21533022);rs2062305 (5e-10,21102463);rs9533090 (5e-25,19801982);rs9594759 (2e-17,19079262);rs9594738 (2e-08,18445777);rs9594759 (2e-21,18445777)
chr13	46832999	46866999	34001	rs958546	5e-06	Atrial fibrillation	rs958546 (5e-06,17903304)
chr13	48131999	48391999	260001	rs8001976;rs1575891;rs2478333	4e-08	Aging (time to event);Cardiac hypertrophy;QT interval	rs8001976 (3e-06,21782286);rs1575891 (6e-06,21348951);rs2478333 (4e-08,20031603)
chr13	51059999	51172999	113001	rs3118906;rs1239954;rs9316500;rs3118905;rs1262778;rs3118914;rs1239947;rs3116602	1e-45	Height;Pubertal anthropometrics;Obesity-related traits;Pulmonary function decline;Bipolar disorder and major depressive disorder (combined)	rs3118906 (2e-24,23563607);rs3118906 (5e-06,23449627);rs1239954 (9e-06,23251661);rs9316500 (5e-06,22424883);rs3118905 (1e-45,20881960);rs1262778 (8e-06,20351715);rs3118914 (4e-10,19343178);rs1239947 (8e-06,18391951);rs3116602 (7e-09,18391952)
chr13	54059999	54130999	71001	rs9568867;rs9568856	2e-09	Obesity	rs9568867 (2e-09,23563607);rs9568856 (2e-09,22484627)
chr13	54571999	54682999	111001	rs9596905;rs9536591	2e-06	DNA methylation (variation);Stroke	rs9596905 (2e-06,23725790);rs9536591 (6e-06,17434096)
chr13	58828999	59166999	338001	rs4886088;rs10492604	4e-06	Subcutaneous adipose tissue;Sleep-related phenotypes	rs4886088 (8e-06,22589738);rs10492604 (4e-06,17903308)
chr13	61389999	61594999	205001	rs7337573	2e-08	Phospholipid levels (plasma)	rs7337573 (2e-08,22359512)
chr13	65426999	66201999	775001	rs1333026	8e-06	Body mass index	rs1333026 (8e-06,17903300)
chr13	69459999	69561999	102001	rs2066219	9e-06	Diabetes related insulin traits	rs2066219 (9e-06,17903298)
chr13	70724999	70865999	141001	rs1928007;rs9572423	5e-06	Word reading;Major depressive disorder	rs1928007 (5e-06,23738518);rs9572423 (9e-06,20125088)
chr13	72327999	72412999	85001	rs584480;rs626277	3e-11	Urate levels;Chronic kidney disease	rs584480 (9e-06,23263486);rs626277 (3e-11,20383146)
chr13	73837999	73934999	97001	rs9573163;rs1886449;rs9543325	5e-13	Pancreatic cancer	rs9573163 (5e-13,22158540);rs1886449 (9e-06,20686608);rs9543325 (3e-11,20101243)
chr13	74714999	74889999	175001	rs12429889;rs8000245	5e-20	Sudden cardiac arrest;Optic nerve measurement (rim area)	rs12429889 (5e-20,21658281);rs8000245 (8e-06,20395239)
chr13	75081999	75147999	66001	rs17718828	1e-08	Phospholipid levels (plasma)	rs17718828 (1e-08,22359512)
chr13	80601999	80757309	155311	rs12431307;rs8001641;rs7981942;rs1359790;rs9574565	9e-11	Obesity-related traits;Orofacial clefts;Fasting insulin-related traits (interaction with BMI);Type 2 diabetes	rs12431307 (5e-06,23251661);rs8001641 (3e-10,22863734);rs8001641 (9e-11,22863734);rs7981942 (2e-06,22581228);rs1359790 (6e-09,20862305);rs9574565 (3e-07,20023658)
chr13	87041999	87983999	942001	rs4773460	2e-06	Hippocampal atrophy	rs4773460 (2e-06,19668339)
chr13	95450999	95475999	25001	rs9302001	3e-07	Panic disorder	rs9302001 (3e-07,19165232)
chr13	103828999	103877999	49001	rs912969	8e-06	Smoking behavior	rs912969 (8e-06,19247474)
chr13	111449999	111505999	56001	rs767210	3e-07	Cognitive performance	rs767210 (3e-07,19734545)
chr14	20953160	20959160	6001	rs12147450	6e-07	Response to antipsychotic therapy (extrapyramidal side effects)	rs12147450 (6e-07,19875103)
chr14	27241160	27283160	42001	rs1951082	5e-06	Attention deficit hyperactivity disorder and conduct disorder	rs1951082 (5e-06,18951430)
chr14	36343249	36429249	86001	rs1168987	5e-06	Response to antineoplastic agents	rs1168987 (5e-06,21659360)
chr14	36498244	36686249	188006	rs1537424;rs944289	2e-09	Thyroid hormone levels;Thyroid cancer	rs1537424 (1e-08,23408906);rs944289 (2e-09,19198613)
chr14	42547250	42699250	152001	rs2154294	3e-06	Alcoholism (12-month weekly alcohol consumption)	rs2154294 (3e-06,21529783)
chr14	49306250	49409250	103001	rs2352904	2e-06	Cognitive test performance	rs2352904 (2e-06,17903297)
chr14	54056250	54104250	48001	rs1380131	9e-06	Alcoholism (heaviness of drinking)	rs1380131 (9e-06,21529783)
chr14	58238247	58449247	211001	rs8013190;rs1335515;rs808225	7e-08	HIV-1 control;Attention deficit hyperactivity disorder (time to onset);Pulmonary function	rs8013190 (7e-08,20041166);rs1335515 (8e-06,18937294);rs808225 (7e-06,17903307)
chr14	59264247	59448247	184001	rs405460;rs4901869	6e-07	Obesity-related traits;Panic disorder	rs405460 (6e-07,23251661);rs4901869 (6e-06,19165232)
chr14	78783247	78796981	13735	rs11624704;rs6574433	3e-09	Obesity;Cognitive performance	rs11624704 (3e-09,21552555);rs6574433 (6e-06,20125193)
chr14	84702247	84789247	87001	rs11159647	2e-06	Alzheimer's disease	rs11159647 (2e-06,18976728)
chr14	87500247	87637247	137001	rs11624056	3e-08	Sudden cardiac arrest	rs11624056 (3e-08,21658281)
chr14	97091247	97175247	84001	rs17094273	9e-08	Tanning	rs17094273 (9e-08,19340012)
chr14	98451247	98678247	227001	rs10142119;rs1456988;rs10144042;rs7140601;rs857228;rs7152623;rs4900384;rs10484128	3e-15	IgE levels in asthmatics (D.f. specific) ;Graves' disease;Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;Immune response to smallpox vaccine (IL-6);Sexual dysfunction (SSRI/SNRI-related);Aortic stiffness;Type 1 diabetes;Hemostatic factors and hematological phenotypes	rs10142119 (2e-07,23967269);rs1456988 (5e-09,23612905);rs10144042 (2e-06,23118302);rs7140601 (7e-07,22542470);rs857228 (3e-06,22445761);rs7152623 (3e-15,22068335);rs4900384 (4e-09,19430480);rs10484128 (6e-06,17903294)
chr14	98812247	98989247	177001	rs1459148	2e-06	Response to antipsychotic therapy (extrapyramidal side effects)	rs1459148 (2e-06,19875103)
chr15	26268907	26297623	28717	rs6576507;rs4906844	1e-08	Insulin resistance/response;Cortical thickness	rs6576507 (4e-07,21901158);rs6576507 (7e-06,21901158);rs4906844 (1e-08,21810643)
chr15	29004959	29012959	8001	rs8033165	2e-12	Black vs. blond hair color;Black vs. red hair color	rs8033165 (5e-11,18483556);rs8033165 (2e-12,18483556)
chr15	34969708	35039708	70001	rs11073058;rs524952;rs634990	1e-15	Axial length;Refractive error	rs11073058 (4e-11,24144296);rs524952 (1e-15,23396134);rs634990 (2e-14,20835239)
chr15	36277708	36350708	73001	rs1898036;rs10520045;rs4923705	2e-07	Response to tocilizumab in rheumatoid arthritis;Major depressive disorder;Attention deficit hyperactivity disorder	rs1898036 (2e-07,22491018);rs10520045 (7e-06,20673876);rs4923705 (2e-06,20732626)
chr15	39112708	39158708	46001	rs2624265	4e-07	Metabolic traits	rs2624265 (4e-07,19060910)
chr15	46617708	46667708	50001	rs4775302	4e-08	Prostate cancer	rs4775302 (4e-08,22130093)
chr15	53264708	53329301	64594	rs719714	4e-08	Cognitive function	rs719714 (4e-08,22126837)
chr15	58668708	58717708	49001	rs2043085;rs1532085;rs920915;rs11857380;rs539901;rs10468017;rs35853021;rs16940212;rs493258;rs4775041	1e-188	Lipid traits;Cholesterol, total;HDL cholesterol;Triglycerides;Age-related macular degeneration;Red blood cell traits;Obesity-related traits;Non-small cell lung cancer;Metabolite levels;Metabolic syndrome;Phospholipid levels (plasma);Lipid metabolism phenotypes;Cardiovascular disease risk factors;Metabolic syndrome (bivariate traits)	rs2043085 (2e-08,24386095);rs1532085 (7e-47,24097068);rs1532085 (1e-188,24097068);rs1532085 (2e-18,24097068);rs920915 (3e-11,23455636);rs1532085 (7e-11,23222517);rs11857380 (3e-06,23251661);rs539901 (8e-06,23144319);rs1532085 (9e-104,22916037);rs1532085 (5e-24,22399527);rs10468017 (7e-43,22359512);rs35853021 (7e-76,22286219);rs10468017 (3e-12,21943158);rs16940212 (1e-24,21909109);rs10468017 (3e-12,21665990);rs2043085 (1e-08,21386085);rs10468017 (6e-08,21386085);rs1532085 (9e-20,20686565);rs1532085 (3e-96,20686565);rs1532085 (2e-13,20686565);rs10468017 (1e-08,20385826);rs493258 (2e-08,20385826);rs1532085 (1e-19,19936222);rs1532085 (9e-15,19936222);rs1532085 (4e-16,19936222);rs1532085 (4e-07,19060911);rs1532085 (1e-35,19060911);rs10468017 (8e-23,19060906);rs1532085 (2e-10,19060910);rs4775041 (1e-07,19043545);rs4775041 (3e-20,18193043);rs4775041 (2e-08,18193043)
chr15	62380708	62417133	36426	rs7172432;rs7173964;rs4502156;rs1436953;rs1436955	4e-20	Type 2 diabetes;Fasting glucose-related traits (interaction with BMI);Proinsulin levels	rs7172432 (1e-06,23945395);rs7173964 (6e-12,22581228);rs4502156 (4e-20,21873549);rs1436953 (8e-06,21799836);rs1436955 (7e-07,20862305);rs7172432 (9e-14,20818381)
chr15	69954946	70051946	97001	rs8026898;rs7176508;rs10152591;rs17374222;rs4776472	4e-19	Rheumatoid arthritis;Chronic lymphocytic leukemia;Height;Atrial fibrillation	rs8026898 (4e-19,24390342);rs8026898 (6e-18,24390342);rs7176508 (8e-18,24292274);rs7176508 (1e-17,23770605);rs7176508 (3e-11,22700719);rs10152591 (3e-10,20881960);rs17374222 (2e-06,20453842);rs7176508 (5e-12,18758461);rs4776472 (8e-06,17903304)
chr15	89581996	89618996	37001	rs420017	7e-06	Obesity-related traits;Height	rs420017 (8e-06,23251661);rs420017 (7e-06,21998595)
chr15	94675996	94723996	48001	rs2388436	6e-06	Hoarding	rs2388436 (6e-06,21302353)
chr15	95238996	95284996	46001	rs7173947	3e-08	Hematological and biochemical traits	rs7173947 (3e-08,20139978)
chr15	96050996	96090996	40001	rs933769	7e-06	Alcoholism (alcohol dependence factor score)	rs933769 (7e-06,21529783)
chr15	96140996	96181996	41001	rs10520789;rs4321143	6e-07	Response to TNF-alpha inhibitors in rheumatoid arthritis;Conduct disorder (interaction)	rs10520789 (6e-07,22569225);rs4321143 (7e-06,18846501)
chr15	96804996	96868996	64001	rs1437588;rs7181753;rs2398162	3e-06	Migraine;Electroencephalographic traits in alcoholism;Hypertension	rs1437588 (3e-06,23793025);rs7181753 (3e-06,22554406);rs2398162 (6e-06,17554300)
chr16	5570000	5614731	44732	rs870288	1e-08	Subcutaneous adipose tissue;Phospholipid levels (plasma)	rs870288 (9e-06,22589738);rs870288 (1e-08,22359512)
chr16	7763000	7842000	79001	rs3112740	6e-06	Smoking behavior	rs3112740 (6e-06,19247474)
chr16	9658500	9754500	96001	rs12325410;rs17550532	1e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Sudden cardiac arrest	rs12325410 (1e-06,23453885);rs17550532 (2e-06,21658281)
chr16	13020500	13120500	100001	rs7192086	6e-06	Schizophrenia	rs7192086 (6e-06,18677311)
chr16	14378041	14451500	73460	rs1659127	1e-11	Menarche (age at onset);Height	rs1659127 (4e-09,21102462);rs1659127 (1e-11,20881960)
chr16	20191008	20268500	77493	rs12597579	1e-08	Body mass index	rs12597579 (1e-08,22344219)
chr16	27050500	27065500	15001	rs2203512	3e-07	Cognitive performance	rs2203512 (3e-07,19734545)
chr16	50844500	50892284	47785	rs16948876	2e-10	Leprosy	rs16948876 (2e-10,22019778)
chr16	50945379	51032500	87122	rs1564981;rs1566045	2e-22	Bone mineral density	rs1564981 (2e-10,22504420);rs1566045 (2e-22,22504420)
chr16	51321500	51426500	105001	rs4131099	4e-06	Personality dimensions	rs4131099 (4e-06,20691247)
chr16	51435500	51498500	63001	rs1362756	5e-09	Optic disc parameters	rs1362756 (5e-09,20548946)
chr16	56980500	56994893	14394	rs3764261;rs9989419;rs247617;rs173539;rs247616	0	Lipid traits;Cholesterol, total;HDL cholesterol;LDL cholesterol;Triglycerides;Lipoprotein-associated phospholipase A2 activity and mass;Metabolite levels;Metabolic syndrome;Lipid metabolism phenotypes;Cardiovascular disease risk factors;Age-related macular degeneration;HDL Cholesterol - Triglycerides (HDLC-TG);Metabolic syndrome (bivariate traits);Hematological and biochemical traits;Waist circumference and related phenotypes	rs3764261 (2e-25,24386095);rs3764261 (4e-31,24097068);rs3764261 (0,24097068);rs3764261 (2e-34,24097068);rs3764261 (2e-25,24097068);rs9989419 (5e-11,24023261);rs247617 (1e-44,23726366);rs247617 (3e-16,23726366);rs3764261 (7e-21,23118302);rs173539 (3e-70,22916037);rs247617 (9e-60,22399527);rs3764261 (1e-36,22286219);rs247616 (3e-08,22003152);rs173539 (3e-65,21943158);rs3764261 (7e-09,21665990);rs173539 (5e-16,21386085);rs173539 (9e-09,21386085);rs3764261 (3e-13,21386085);rs173539 (1e-16,21386085);rs9989419 (1e-32,20864672);rs247616 (1e-23,20838585);rs3764261 (7e-14,20686565);rs3764261 (0,20686565);rs3764261 (9e-13,20686565);rs3764261 (1e-12,20686565);rs3764261 (1e-48,20694148);rs3764261 (5e-29,20139978);rs3764261 (3e-12,19359809);rs173539 (4e-75,19060906);rs3764261 (7e-29,19060910);rs9989419 (9e-27,20031538);rs3764261 (1e-27,18454146);rs3764261 (2e-57,18193043);rs9989419 (3e-31,18193043)
chr16	60314488	60356861	42374	rs9932186	3e-08	Phospholipid levels (plasma)	rs9932186 (3e-08,22359512)
chr16	61122500	61453500	331001	rs2639889	9e-07	Morbidity-free survival	rs2639889 (9e-07,17903295)
chr16	63952500	64119500	167001	rs1381102	6e-06	Attention deficit hyperactivity disorder and conduct disorder	rs1381102 (6e-06,18951430)
chr16	73005821	73079500	73680	rs879324;rs2106261;rs7193343;rs7199343	3e-16	Stroke (ischemic);Atrial fibrillation;Kawasaki disease	rs879324 (2e-08,23041239);rs2106261 (3e-16,22544366);rs2106261 (2e-15,19597492);rs7193343 (1e-10,19597491);rs7199343 (2e-06,19132087)
chr16	73467500	73507500	40001	rs12446956	1e-06	Major depressive disorder	rs12446956 (1e-06,21042317)
chr16	76652500	76900500	248001	rs113716969;rs17679567;rs13330107	2e-06	Serum dimethylarginine levels (asymmetric/symetric ratio);Response to TNF-alpha inhibitors in rheumatoid arthritis;Inattentive symptoms	rs113716969 (2e-06,24159190);rs17679567 (9e-06,22569225);rs13330107 (9e-06,18821565)
chr16	79667014	79760500	93487	rs3813582;rs7188445;rs17767419;rs3813579;rs1424233	8e-18	Thyroid hormone levels;Urate levels;Thyroid function;Thyroid volume;Obesity	rs3813582 (8e-18,23408906);rs3813582 (6e-17,23408906);rs7188445 (2e-09,23263486);rs3813582 (6e-10,22494929);rs17767419 (9e-15,21565293);rs3813579 (4e-10,21565293);rs1424233 (4e-13,19151714)
chr16	80495564	80560500	64937	rs4581712	3e-09	Liver enzyme levels (gamma-glutamyl transferase)	rs4581712 (3e-09,22001757)
chr16	82309500	82413500	104001	rs11863065;rs4082514;rs4087296	1e-07	Obesity-related traits;Cognitive performance;Bone mineral density	rs11863065 (4e-07,23251661);rs11863065 (1e-06,23251661);rs11863065 (1e-07,23251661);rs11863065 (5e-06,23251661);rs11863065 (9e-07,23251661);rs11863065 (9e-06,23251661);rs11863065 (3e-06,23251661);rs4082514 (3e-06,19734545);rs4087296 (3e-07,17903296)
chr16	85980500	86024500	44001	rs13330176;rs16940186;rs16940202;rs10521318;rs2280381;rs13333054;rs11642873;rs11117432;rs17445836	6e-19	Rheumatoid arthritis;Ulcerative colitis;Inflammatory bowel disease;Multiple sclerosis;Systemic sclerosis;Primary biliary cirrhosis	rs13330176 (9e-09,24390342);rs13330176 (1e-12,24390342);rs16940186 (4e-10,23511034);rs16940202 (3e-09,23511034);rs10521318 (1e-09,23128233);rs2280381 (2e-06,22446963);rs13333054 (1e-08,21833088);rs11642873 (2e-12,21779181);rs11117432 (5e-11,21399635);rs16940202 (6e-19,21297633);rs17445836 (4e-09,19525953)
chr16	86635500	86736500	101001	rs71390846;rs300032;rs1867485;rs10048146	1e-14	Bone mineral density;IgG glycosylation;Obesity-related traits;Bone mineral density (hip);Bone mineral density (spine)	rs71390846 (2e-10,24249740);rs71390846 (2e-06,24249740);rs300032 (9e-08,23382691);rs300032 (3e-07,23382691);rs1867485 (3e-06,23251661);rs10048146 (1e-14,22504420);rs10048146 (2e-07,19801982);rs10048146 (2e-08,19801982)
chr16	88197500	88345507	148008	rs6540223;rs9938149;rs12447690	2e-49	Axial length;Corneal structure;Central corneal thickness	rs6540223 (7e-08,24144296);rs9938149 (2e-49,23291589);rs9938149 (1e-12,22814818);rs12447690 (6e-22,20719862);rs12447690 (9e-11,20485516)
chr17	10004276	10035336	31061	rs12150284;rs11656696	1e-08	Intraocular pressure	rs12150284 (2e-06,24002674);rs11656696 (1e-08,22570627)
chr17	13684276	13739276	55001	rs7215286;rs4792394;rs12949531	3e-06	IgG glycosylation;Conduct disorder (symptom count);Systemic lupus erythematosus	rs7215286 (3e-06,23382691);rs4792394 (9e-06,20585324);rs12949531 (8e-06,19165918)
chr17	14284276	14300276	16001	rs3848445	8e-09	Protein quantitative trait loci	rs3848445 (8e-09,18464913)
chr17	49570480	49628002	57523	rs9635759	7e-13	Menarche (age at onset)	rs9635759 (7e-13,21102462)
chr17	51118002	51289002	171001	rs8073783	8e-06	Conduct disorder (interaction)	rs8073783 (8e-06,18846501)
chr17	54741087	54802002	60916	rs227731;rs227724	7e-15	Orofacial clefts;Height	rs227731 (2e-08,22863734);rs227724 (7e-15,20881960);rs227731 (1e-08,20023658)
chr17	68255406	68741406	486001	rs4793501;rs16975985;rs312691;rs623011;rs7219669;rs17718586;rs6501384;rs17779747	6e-14	Refractive error;Obesity-related traits;Thyrotoxic hypokalemic periodic paralysis;Cardiac repolarization;Sudden cardiac arrest;Eosinophilic esophagitis (pediatric);QT interval	rs4793501 (3e-08,23396134);rs16975985 (5e-06,23251661);rs312691 (8e-14,22863731);rs623011 (4e-12,22399142);rs7219669 (6e-14,22342860);rs17718586 (2e-08,21658281);rs6501384 (6e-06,20208534);rs17779747 (6e-12,19305409)
chr17	69102406	69244406	142001	rs12946942;rs11654749;rs1859962	2e-16	Adolescent idiopathic scoliosis (severe);Pulmonary function (interaction);Prostate cancer	rs12946942 (6e-12,24023777);rs11654749 (1e-08,23284291);rs11654749 (7e-08,23284291);rs1859962 (3e-11,21743057);rs1859962 (2e-16,19767753);rs1859962 (1e-06,18264097);rs1859962 (3e-10,17603485)
chr17	69790406	69966406	176001	rs7217932	2e-11	Bone mineral density	rs7217932 (2e-11,22504420)
chr18	4766001	4844001	78001	rs7237848	2e-07	White blood cell types	rs7237848 (2e-07,21738478)
chr18	20137003	20295003	158001	rs4331426;rs11661542	1e-12	Tuberculosis;Intracranial aneurysm	rs4331426 (2e-08,24057671);rs4331426 (7e-09,20694014);rs11661542 (1e-12,20364137)
chr18	25761003	26259003	498001	rs11659841;rs879500;rs4800843;rs11083271;rs4131805	2e-06	Periodontal disease-related phenotypes;Lung function (forced vital capacity);Response to amphetamines;Non-alcoholic fatty liver disease histology (lobular);Hip geometry	rs11659841 (9e-06,24347629);rs879500 (5e-06,24023788);rs4800843 (3e-06,22952603);rs11083271 (8e-06,20708005);rs4131805 (2e-06,17903296)
chr18	31389003	31425003	36001	rs1013696	4e-06	Response to antidepressants	rs1013696 (4e-06,20360315)
chr18	47144222	47185003	40782	rs7241918;rs7228085;rs2156552;rs4939883;rs7240405	3e-49	Cholesterol, total;HDL cholesterol;Lipid metabolism phenotypes	rs7241918 (4e-18,24097068);rs7241918 (1e-44,24097068);rs7228085 (7e-11,22286219);rs2156552 (2e-12,20864672);rs7241918 (2e-19,20686565);rs7241918 (3e-49,20686565);rs4939883 (6e-14,19936222);rs4939883 (2e-11,19936222);rs4939883 (2e-08,19936222);rs4939883 (1e-09,19936222);rs4939883 (5e-13,19936222);rs4939883 (7e-16,19936222);rs4939883 (4e-10,19936222);rs4939883 (2e-11,19060911);rs4939883 (7e-15,19060906);rs7240405 (5e-10,20031538);rs2156552 (2e-07,18193044);rs2156552 (6e-12,18193043)
chr18	52713003	52766003	53001	rs4801131;rs12966547	3e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	rs4801131 (1e-08,23974872);rs12966547 (3e-10,23453885);rs12966547 (3e-08,21926974)
chr18	53631003	53695003	64001	rs1978503	1e-06	Breast cancer	rs1978503 (1e-06,17903305)
chr18	57454021	57512021	58001	rs8093763	3e-08	Bleomycin sensitivity	rs8093763 (3e-08,21106707)
chr18	57730095	57917021	186927	rs6567160;rs12967135;rs7234864;rs8089364;rs538656;rs11152213;rs10871777;rs476828;rs12955983;rs489693;rs2331841;rs571312;rs17782313;rs12957347;rs12970134	6e-42	Body mass index;Fat body mass;HDL cholesterol;Obesity;Obesity (early onset extreme);Urate levels;Antipsychotic drug-induced weight gain;Height;Metabolic syndrome;Waist circumference;Weight;Waist circumference and related phenotypes	rs6567160 (8e-19,24064335);rs6567160 (3e-11,24064335);rs12967135 (4e-08,24097068);rs7234864 (4e-17,23669352);rs8089364 (4e-21,23563607);rs538656 (2e-36,23563607);rs11152213 (3e-22,23563607);rs10871777 (2e-27,23563607);rs476828 (9e-14,23563609);rs12955983 (2e-06,23263486);rs489693 (6e-12,22566560);rs2331841 (2e-11,22344221);rs571312 (6e-42,20935630);rs17782313 (4e-11,20881960);rs12967135 (7e-09,20686565);rs12957347 (7e-06,20694148);rs489693 (4e-07,19557197);rs17782313 (5e-15,19151714);rs12970134 (1e-12,19079260);rs12970134 (5e-13,19079260);rs17782313 (5e-18,19079261);rs12970134 (2e-09,18454146);rs17782313 (3e-15,18454148)
chr18	62898021	63032021	134001	rs637644;rs8083346;rs470490	5e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);D-dimer levels;Atrioventricular conduction	rs637644 (7e-06,24025145);rs8083346 (6e-06,21502573);rs470490 (5e-06,21041692)
chr18	65319021	65489021	170001	rs11660238;rs74789784;rs75687134;rs114535501;rs11661646;rs13353224	2e-06	Bipolar disorder (body mass index interaction);Hyperactive-impulsive symptoms	rs11660238 (2e-06,24322204);rs74789784 (2e-06,24322204);rs75687134 (2e-06,24322204);rs114535501 (6e-06,24322204);rs11661646 (6e-06,24322204);rs13353224 (9e-06,18821565)
chr18	68119021	68188021	69001	rs8092443;rs11663206	1e-06	Response to antipsychotic treatment	rs8092443 (1e-06,20195266);rs11663206 (2e-06,20195266)
chr18	68621021	68674021	53001	rs2660917	8e-06	Iron status biomarkers	rs2660917 (8e-06,19084217)
chr18	71039021	71069021	30001	rs1943816	1e-07	Cerebrospinal P-tau181p levels	rs1943816 (1e-07,20932310)
chr19	3302001	3320001	18001	rs11669592	4e-06	Non-alcoholic fatty liver disease histology (other)	rs11669592 (4e-06,20708005)
chr19	8776879	8796159	19281	rs2164983	7e-09	Atopic dermatitis	rs2164983 (7e-09,22197932)
chr19	18808914	18850707	41794	rs10423674	6e-09	Menarche (age at onset)	rs10423674 (6e-09,21102462)
chr19	22731161	22770161	39001	rs8111998	8e-07	Corneal structure	rs8111998 (8e-07,21979947)
chr19	33723161	33766161	43001	rs17694108;rs736289;rs10500264	6e-15	Inflammatory bowel disease;Crohn's disease;Inflammatory bowel disease (early onset)	rs17694108 (6e-15,23128233);rs736289 (9e-09,21102463);rs10500264 (4e-10,19915574)
chr2	596001	656001	60001	rs939583;rs12463617;rs2903492;rs6711012;rs10189761;rs2947411;rs2867125;rs11127485;rs7561317;rs6548238	3e-49	Body mass index;Obesity;Obesity (early onset extreme);Menarche (age at onset);Weight	rs939583 (1e-07,24064335);rs12463617 (3e-17,23669352);rs2903492 (6e-15,23563607);rs6711012 (3e-40,23563607);rs10189761 (6e-24,23563607);rs6711012 (6e-35,23563607);rs12463617 (2e-13,23563609);rs2947411 (2e-08,21102462);rs2867125 (3e-49,20935630);rs11127485 (2e-07,20421936);rs7561317 (4e-17,19079260);rs7561317 (2e-18,19079260);rs6548238 (1e-18,19079261)
chr2	9875550	9940550	65001	rs2357266	4e-06	Self-rated health	rs2357266 (4e-06,20707712)
chr2	12604550	12706550	102001	rs1534422	2e-06	Type 1 diabetes	rs1534422 (2e-06,19430480)
chr2	18202520	18268520	66001	rs4075511;rs16984239	2e-06	Temperament (bipolar disorder);Amyotrophic lateral sclerosis	rs4075511 (3e-06,22365631);rs16984239 (2e-06,17362836)
chr2	18492520	18550520	58001	rs7580332	9e-06	Amyotrophic lateral sclerosis	rs7580332 (9e-06,18084291)
chr2	22606496	22903496	297001	rs13015955;rs17043947	2e-07	Coronary heart disease;Self-rated health	rs13015955 (4e-07,21347282);rs17043947 (2e-07,20707712)
chr2	23355496	23504496	149001	rs1449984	7e-06	Depression (quantitative trait)	rs1449984 (7e-06,20800221)
chr2	24687497	24745497	58001	rs2165738	4e-06	Type 1 diabetes	rs2165738 (4e-06,18978792)
chr2	34393497	34555497	162001	rs6733379	4e-06	Attention deficit hyperactivity disorder and conduct disorder	rs6733379 (4e-06,18951430)
chr2	35318497	35668497	350001	rs13402855;rs6750486	2e-06	Metabolite levels (5-HIAA);Conduct disorder (symptom count)	rs13402855 (2e-06,23319000);rs6750486 (6e-06,20585324)
chr2	37735497	37877497	142001	rs4352210	2e-06	RR interval (heart rate)	rs4352210 (2e-06,20031603)
chr2	41900497	42018497	118001	rs719593	5e-06	Conduct disorder (interaction)	rs719593 (5e-06,18846501)
chr2	43321224	43361388	40165	rs6718520;rs12466022	6e-10	Multiple sclerosis	rs6718520 (3e-08,22190364);rs12466022 (6e-10,21833088)
chr2	46342350	46371213	28864	rs13008603;rs4953318;rs10495928;rs10168349	3e-19	Red blood cell traits;Hematological and biochemical traits;Red blood cell count;Hematocrit;Hemoglobin	rs13008603 (4e-09,23446634);rs4953318 (3e-19,23222517);rs10495928 (5e-06,20139978);rs10168349 (5e-07,20139978);rs10495928 (4e-08,20139978);rs10168349 (4e-15,19862010);rs10495928 (7e-13,19862010)
chr2	49906497	49966497	60001	rs17039212	9e-06	Systemic lupus erythematosus	rs17039212 (9e-06,19165918)
chr2	52996497	53282497	286001	rs1160297;rs2357013	1e-06	Hemostatic factors and hematological phenotypes	rs1160297 (1e-06,17903294);rs2357013 (6e-06,17903294)
chr2	58904497	59098497	194001	rs6719884;rs17552189	3e-06	Myasthenia gravis ;Cannabis dependence	rs6719884 (3e-06,23055271);rs17552189 (4e-06,21668797)
chr2	59272350	59339350	67001	rs887912;rs991964	2e-12	Obesity;Uterine fibroids;Body mass index	rs887912 (1e-10,23563607);rs887912 (6e-09,23563607);rs991964 (9e-06,21460842);rs887912 (2e-12,20935630)
chr2	60412497	60591497	179001	rs359268;rs6545803;rs243021;rs10202231	3e-15	Hypersomnia (HLA-DQB1*06:02 negative);Nevirapine-induced rash;Type 2 diabetes;Response to antipsychotic treatment	rs359268 (1e-06,23646285);rs6545803 (6e-06,21810746);rs243021 (3e-15,20581827);rs10202231 (7e-07,20195266)
chr2	62543497	62608497	65001	rs10865331	7e-34	Crohn's disease;Ankylosing spondylitis	rs10865331 (1e-09,23128233);rs10865331 (7e-34,21743469);rs10865331 (2e-19,20062062)
chr2	62702350	62723473	21124	rs6545946	7e-09	Crohn's disease	rs6545946 (7e-09,22412388)
chr2	68030350	68145497	115148	rs6747972	9e-11	Restless legs syndrome	rs6747972 (9e-11,21779176)
chr2	77980493	78095493	115001	rs7595103	7e-06	Attention deficit hyperactivity disorder and conduct disorder	rs7595103 (7e-06,18951430)
chr2	79613493	79784493	171001	rs2100290;rs399885;rs7570469	5e-07	Alcohol consumption;Response to antipsychotic treatment	rs2100290 (2e-06,23942779);rs399885 (5e-07,20195266);rs7570469 (6e-07,20195266)
chr2	81525490	82266490	741001	rs6736587;rs12615721;rs12052359;rs10496265;rs10496262	1e-08	Orthostatic hypotension;Pulmonary function decline;Bilirubin levels;Aging traits	rs6736587 (5e-08,24124408);rs12615721 (8e-06,22424883);rs12052359 (7e-06,22085899);rs10496265 (1e-08,17903295);rs10496262 (3e-07,17903295)
chr2	83002490	83543490	541001	rs17022444	1e-10	Response to antipsychotic therapy (extrapyramidal side effects)	rs17022444 (1e-10,19875103)
chr2	84004490	84382490	378001	rs13398848;rs1534238;rs1447537	1e-06	Conduct disorder;Conduct disorder (symptom count);Response to antipsychotic treatment;RR interval (heart rate)	rs13398848 (5e-06,20585324);rs13398848 (1e-06,20585324);rs1534238 (3e-06,20195266);rs1447537 (4e-06,20031603)
chr2	109626483	109650483	24001	rs4676049	4e-08	Alzheimer's disease (late onset)	rs4676049 (4e-08,20885792)
chr2	119013360	119208103	194744	rs1878526	1e-10	Bone mineral density	rs1878526 (1e-10,22504420)
chr2	119817531	119875531	58001	rs17189298	3e-07	Cerebrospinal T-tau levels	rs17189298 (3e-07,20932310)
chr2	123554531	123771531	217001	rs17367118	9e-06	Attention deficit hyperactivity disorder	rs17367118 (9e-06,18821565)
chr2	137279531	137430531	151001	rs934299	9e-06	Cognitive test performance	rs934299 (9e-06,17903297)
chr2	146089531	146462531	373001	rs13407123;rs10445672;rs10427255	1e-11	Attention deficit hyperactivity disorder (inattention symptoms);Obesity-related traits;Common traits (Other)	rs13407123 (8e-06,23527680);rs10445672 (8e-06,23251661);rs10427255 (1e-11,20585627)
chr2	147205531	147643531	438001	rs10928302	8e-06	HIV-1 control	rs10928302 (8e-06,20041166)
chr2	151005755	151153755	148001	rs6716455	7e-07	Alcoholism (alcohol dependence factor score);Alcoholism (alcohol use disorder factor score)	rs6716455 (9e-06,21529783);rs6716455 (7e-07,21529783)
chr2	156882755	157178493	295739	rs17188434;rs16839962;rs1918172	1e-09	Menarche (age at onset);Response to statin therapy;Attention deficit hyperactivity disorder	rs17188434 (1e-09,21102462);rs16839962 (9e-06,20339536);rs1918172 (5e-06,18821565)
chr2	164720198	165134494	414297	rs13002573;rs1446468;rs16849225	6e-12	Blood pressure	rs13002573 (2e-08,21909110);rs1446468 (6e-12,21909110);rs16849225 (4e-11,21572416)
chr2	176213755	176517755	304001	rs4972755;rs2461751	3e-06	Bipolar disorder and major depressive disorder (combined);Electrocardiographic conduction measures	rs4972755 (3e-06,20351715);rs2461751 (8e-06,19389651)
chr2	177761755	177956755	195001	rs1529093	2e-06	Non-alcoholic fatty liver disease histology (other)	rs1529093 (2e-06,20708005)
chr2	180564495	180568495	4001	rs16866933	6e-14	Sudden cardiac arrest	rs16866933 (6e-14,21658281)
chr2	181430756	181634756	204001	rs918959	2e-06	Systemic lupus erythematosus	rs918959 (2e-06,21408207)
chr2	181969930	182139107	169178	rs13010713;rs1018326	5e-11	Celiac disease;Ankylosing spondylitis	rs13010713 (5e-11,20190752);rs1018326 (2e-06,20062062)
chr2	193231756	193447756	216001	rs1385351	4e-06	HIV-1 control	rs1385351 (4e-06,20041166)
chr2	193740495	194753495	1013001	rs17662626;rs10174573	5e-08	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Major depressive disorder;Schizophrenia	rs17662626 (5e-08,23453885);rs10174573 (2e-06,23377640);rs17662626 (5e-08,21926974)
chr2	194869756	195238756	369001	rs2176528	4e-06	Bipolar disorder	rs2176528 (4e-06,21926972)
chr2	199606495	199659495	53001	rs12617311	6e-13	Menarche (age at onset)	rs12617311 (6e-13,21102462)
chr2	213799495	213853254	53760	rs12619285	5e-10	Eosinophil counts	rs12619285 (5e-10,19198610)
chr2	217853495	217973756	120262	rs10932688;rs13387042;rs4491709;rs6435957	2e-57	Primary tooth development (number of teeth);Breast cancer;Permanent tooth development	rs10932688 (3e-08,23704328);rs13387042 (2e-57,23535729);rs4491709 (2e-14,21931568);rs13387042 (2e-10,21263130);rs13387042 (9e-06,20872241);rs13387042 (2e-10,20453838);rs6435957 (4e-07,20195514);rs13387042 (2e-08,19330030);rs13387042 (1e-13,17529974)
chr2	218098756	218271756	173001	rs6759952;rs2553026	6e-10	Thyroid cancer;Height	rs6759952 (6e-10,23894154);rs2553026 (6e-08,21998595)
chr2	221805757	221928757	123001	rs10498091	6e-06	Echocardiographic traits	rs10498091 (6e-06,17903301)
chr2	226230757	226244757	14001	rs1517484	5e-07	Attention deficit hyperactivity disorder (time to onset)	rs1517484 (5e-07,18937294)
chr2	227018496	227201496	183001	rs2972146;rs2943636;rs2943634;rs2943640;rs1515110;rs925735;rs2943650;rs7578326;rs2943641	5e-20	HDL cholesterol;Triglycerides;Sexual dimorphism in anthropometric traits;Fasting insulin-related traits (interaction with BMI);Visceral adipose tissue/subcutaneous adipose tissue ratio;Adiponectin levels;Adiposity;Type 2 diabetes;Type 2 diabetes and other traits;Coronary heart disease	rs2972146 (2e-17,24097068);rs2972146 (3e-15,24097068);rs2943636 (2e-07,23754948);rs2943634 (2e-14,22581228);rs2943640 (4e-06,22589738);rs1515110 (2e-07,22479202);rs925735 (2e-08,22479202);rs2943650 (4e-11,21706003);rs2972146 (2e-09,20686565);rs2972146 (2e-08,20686565);rs7578326 (5e-20,20581827);rs2943641 (9e-12,19734900);rs2943634 (2e-07,17634449)
chr2	227498757	227582757	84001	rs7558386	1e-07	Cerebrospinal P-tau181p levels	rs7558386 (1e-07,20932310)
chr2	239857747	239905747	48001	rs12477314	2e-12	Pulmonary function (interaction);Pulmonary function	rs12477314 (2e-07,23284291);rs12477314 (2e-12,21946350);rs12477314 (1e-07,21946350)
chr2	240418064	240489064	71001	rs6743931	2e-06	Response to antipsychotic therapy (extrapyramidal side effects)	rs6743931 (2e-06,19875103)
chr20	1920577	1950857	30281	rs6035126;rs13042885;rs6045676;rs6136489	6e-14	Liver enzyme levels (alanine transaminase);Mean platelet volume;Aortic root size	rs6035126 (5e-06,24124411);rs13042885 (6e-14,22139419);rs6045676 (3e-08,21223598);rs6136489 (8e-11,19820697)
chr20	4096225	4108001	11777	rs1741344	3e-09	Height	rs1741344 (3e-09,20881960)
chr20	6275001	6409001	134001	rs6085533;rs961253	2e-10	Metabolite levels  (X-11787);Colorectal cancer	rs6085533 (1e-06,23934736);rs961253 (2e-10,19011631)
chr20	6570520	6644001	73482	rs6107853;rs2145270;rs2145272;rs967417	2e-24	Body mass index;Height	rs6107853 (2e-06,23669352);rs2145270 (5e-18,23563607);rs2145272 (2e-24,20881960);rs2145270 (6e-06,19079261);rs967417 (2e-08,18391951)
chr20	7551001	7600001	49001	rs6108011	6e-06	Hemostatic factors and hematological phenotypes	rs6108011 (6e-06,17903294)
chr20	12828001	12894001	66001	rs2073233	1e-06	Brain structure	rs2073233 (1e-06,20171287)
chr20	12930001	12983001	53001	rs364585;rs680379	2e-16	LDL cholesterol;Sphingolipid levels	rs364585 (4e-10,24097068);rs680379 (2e-16,22359512);rs680379 (8e-15,19798445)
chr20	14696432	14864887	168456	rs4141463	4e-08	Autism	rs4141463 (4e-08,20663923)
chr20	17050168	17159075	108908	rs852069	3e-08	Menarche (age at onset)	rs852069 (3e-08,21102462)
chr20	21760834	22186592	425759	rs6047844;rs2180439;rs1160312	2e-39	Male-pattern baldness	rs6047844 (2e-39,22693459);rs2180439 (4e-17,22032556);rs2180439 (3e-15,18849994);rs1160312 (1e-14,18849991)
chr20	38950578	39117994	167417	rs2902940;rs8124695	2e-11	Cholesterol, total;LDL cholesterol;Dupuytren's disease	rs2902940 (9e-10,24097068);rs2902940 (2e-11,24097068);rs8124695 (8e-10,21732829);rs2902940 (6e-11,20686565);rs2902940 (1e-08,20686565)
chr20	39143297	39238587	95291	rs6102059	4e-09	LDL cholesterol	rs6102059 (4e-09,19060906)
chr20	45422594	45486594	64001	rs6066084	2e-06	Quantitative traits	rs6066084 (2e-06,19197348)
chr20	51299594	51321594	22001	rs6013509	1e-10	Hemoglobin	rs6013509 (1e-10,19862010)
chr20	52301594	52356594	55001	rs6091737	6e-06	Calcium levels	rs6091737 (6e-06,20705733)
chr20	53620594	54054594	434001	rs6092078	3e-06	Response to antipsychotic treatment	rs6092078 (3e-06,20195266)
chr20	55990404	55995788	5385	rs737092;rs6092477	4e-13	Red blood cell traits;Mean corpuscular volume	rs737092 (4e-13,23222517);rs6092477 (1e-08,20139978)
chr20	59176606	59329606	153001	rs6027755	6e-06	Non-alcoholic fatty liver disease histology (other)	rs6027755 (6e-06,20708005)
chr21	16736036	16842129	106094	rs2823286;rs1297265;rs1736020;rs1736135	9e-30	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease	rs2823286 (9e-30,23128233);rs1297265 (7e-13,21297633);rs1736020 (9e-12,21102463);rs1736135 (2e-07,20228799);rs1736135 (7e-09,18587394)
chr21	20475129	20674129	199001	rs2825388	8e-06	Attention deficit hyperactivity disorder symptoms (interaction)	rs2825388 (8e-06,18846501)
chr21	21880129	21907129	27001	rs2826340	2e-06	Attention deficit hyperactivity disorder and conduct disorder	rs2826340 (2e-06,18951430)
chr21	23506129	23633129	127001	rs2827312	8e-06	Alcoholism (heaviness of drinking)	rs2827312 (8e-06,21529783)
chr21	24167129	24217129	50001	rs7279441	8e-06	Self-rated health	rs7279441 (8e-06,20707712)
chr21	25092129	25219129	127001	rs2828520	4e-07	Major depressive disorder	rs2828520 (4e-07,20125088)
chr21	26508129	26762129	254001	rs9977253	5e-06	Non-alcoholic fatty liver disease histology (other)	rs9977253 (5e-06,20708005)
chr21	28632129	28711129	79001	rs457603;rs239713;rs2830840	5e-07	Liver enzyme levels (aspartate transaminase);Cerebrospinal AB1-42 levels;Response to citalopram treatment	rs457603 (5e-06,24124411);rs239713 (5e-07,20932310);rs2830840 (5e-06,19846067)
chr21	29448129	29517129	69001	rs9305354	8e-06	Urinary albumin excretion	rs9305354 (8e-06,17903292)
chr21	35588130	35721559	133430	rs9982601 ;rs1013063;rs9978142;rs9982601;rs2834442	5e-12	Coronary artery disease;Body mass index (interaction);Pulmonary function;Coronary heart disease;Height;Myocardial infarction (early onset)	rs9982601  (3e-10,24262325);rs1013063 (5e-06,23192594);rs9978142 (3e-08,21946350);rs9982601 (4e-10,21378990);rs2834442 (5e-12,20881960);rs9982601 (6e-11,19198609)
chr21	36338130	36370072	31943	rs2014300	8e-22	Esophageal cancer	rs2014300 (8e-22,21642993)
chr21	40386130	40485130	99001	rs4817986;rs2836878;rs378108;rs2242944	5e-48	Fibrinogen;Inflammatory bowel disease;Ankylosing spondylitis;C-reactive protein;Ulcerative colitis	rs4817986 (2e-11,23969696);rs2836878 (5e-48,23128233);rs378108 (2e-11,21743469);rs2836878 (2e-07,21300955);rs2836878 (2e-22,21297633);rs2242944 (8e-20,20062062);rs2836878 (4e-12,18758464)
chr21	44735572	44774572	39001	rs643608	1e-06	Non-alcoholic fatty liver disease histology (other)	rs643608 (1e-06,20708005)
chr22	28036000	28125000	89001	rs5762311	7e-06	Sudden cardiac arrest	rs5762311 (7e-06,21658281)
chr22	34795000	35135000	340001	rs55794228;rs4821261;rs1034394;rs738968;rs130575	8e-08	Serum dimethylarginine levels (symmetric);Behavioural disinhibition (generation interaction);Major depressive disorder;Immune reponse to smallpox (secreted TNF-alpha);Attention deficit hyperactivity disorder	rs55794228 (7e-06,24159190);rs4821261 (9e-06,23942779);rs1034394 (2e-06,23377640);rs738968 (8e-08,22610502);rs130575 (5e-06,18821565)
chr22	43491268	43504502	13235	rs5759167	6e-29	Prostate cancer	rs5759167 (6e-29,19767753)
chr22	48213336	48335336	122001	rs9627183	3e-06	Attention deficit hyperactivity disorder	rs9627183 (3e-06,18821564)
chr22	48902481	48932481	30001	rs80088139;rs5768709	1e-10	Bipolar disorder (body mass index interaction);Pancreatic cancer	rs80088139 (5e-06,24322204);rs5768709 (1e-10,22158540)
chr3	1857046	1912001	54956	rs2727943	3e-08	Bipolar disorder	rs2727943 (3e-08,22205951)
chr3	3585001	3659565	74565	rs10865864;rs9837561;rs9815663;rs1601875	2e-08	Callous-unemotional behaviour;Response to amphetamines;Asthma (childhood onset);Bipolar disorder	rs10865864 (4e-06,23874384);rs9837561 (3e-06,22952603);rs9815663 (2e-08,22560479);rs1601875 (7e-06,18711365)
chr3	7851001	7991001	140001	rs4591494	9e-06	Factor VII	rs4591494 (9e-06,17903294)
chr3	18606997	18828997	222001	rs4256159;rs13073817;rs6809854	9e-15	Inflammatory bowel disease;Crohn's disease;Psoriasis	rs4256159 (9e-15,23128233);rs13073817 (7e-09,21102463);rs6809854 (1e-07,20953190)
chr3	21899997	22063997	164001	rs11719664	2e-06	Attention deficit hyperactivity disorder	rs11719664 (2e-06,18821565)
chr3	28039997	28124997	85001	rs170934;rs669607	2e-15	Multiple sclerosis	rs170934 (2e-08,22190364);rs669607 (2e-15,21833088)
chr3	30342997	30425997	83001	rs7634533;rs10510634	5e-06	Dental caries;Fasting plasma glucose	rs7634533 (5e-06,23259602);rs10510634 (5e-06,17903298)
chr3	34812997	35023997	211001	rs10514688	6e-06	Tonometry	rs10514688 (6e-06,17903302)
chr3	41072354	41198997	126644	rs430727;rs87938;rs10490823	4e-25	Bone mineral density;Bone mineral density (hip)	rs430727 (4e-25,22504420);rs87938 (8e-10,19801982);rs10490823 (9e-06,19079262)
chr3	56844961	56902961	58001	rs1354034;rs12485738	3e-69	Mean platelet volume;Platelet counts	rs1354034 (9e-34,24026423);rs1354034 (6e-24,24026423);rs1354034 (9e-13,23263863);rs1354034 (4e-09,23263863);rs1354034 (1e-19,23263863);rs1354034 (3e-69,22139419);rs1354034 (3e-54,22139419);rs12485738 (6e-31,19820697);rs12485738 (4e-27,19110211)
chr3	64694961	64734961	40001	rs2371767;rs6795735;rs7638389;rs7433808;rs4607103	5e-09	Sexual dimorphism in anthropometric traits;Age-related macular degeneration;Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;Type 2 diabetes	rs2371767 (2e-06,23754948);rs6795735 (5e-09,23455636);rs7638389 (8e-06,22589738);rs7433808 (2e-07,22589738);rs4607103 (1e-08,18372903)
chr3	66743311	66830311	87001	rs13069000;rs17045031;rs13069049;rs11709625	1e-19	Renal function-related traits (BUN);Carotid intima media thickness;Metabolite levels;Hematological and biochemical traits	rs13069000 (1e-19,22797727);rs17045031 (4e-07,21909108);rs13069049 (3e-18,21909109);rs11709625 (1e-10,20139978)
chr3	78340311	78473311	133001	rs9831754	8e-06	Calcium levels	rs9831754 (8e-06,20705733)
chr3	84191311	84764311	573001	rs4522784;rs10511089	7e-07	Obesity-related traits;Brain structure	rs4522784 (7e-06,23251661);rs10511089 (7e-07,20171287)
chr3	86740252	86986052	245801	rs7628864;rs17023661;rs9757252;rs7642134	4e-10	Pubertal anthropometrics;Obesity-related traits;Prostate cancer (gene x gene interaction);Menarche (age at onset)	rs7628864 (3e-09,23449627);rs17023661 (2e-06,23251661);rs9757252 (5e-06,22219177);rs7642134 (4e-10,21102462)
chr3	87088311	87237220	148910	rs17023900;rs9284813;rs17181170;rs2660753	5e-09	Prostate cancer	rs17023900 (6e-08,22923026);rs9284813 (5e-09,20676098);rs17181170 (3e-08,19767753);rs2660753 (3e-08,18264097)
chr3	99046311	99190311	144001	rs2670321	2e-06	RR interval (heart rate)	rs2670321 (2e-06,20031603)
chr3	101671311	101809311	138001	rs771767;rs991258	9e-09	Multiple sclerosis;Hip geometry	rs771767 (9e-09,21833088);rs991258 (5e-07,17903296)
chr3	106213311	106335311	122001	rs12491921	1e-06	Cannabis dependence	rs12491921 (1e-06,21668797)
chr3	117237311	117345311	108001	rs72951640;rs1875517	2e-06	Serum dimethylarginine levels (asymmetric);Waist circumference	rs72951640 (5e-06,24159190);rs1875517 (2e-06,17903300)
chr3	117445311	117823311	378001	rs6438424	1e-13	Menarche (age at onset)	rs6438424 (1e-13,21102462)
chr3	124308780	124345165	36386	rs10512627	5e-10	Mean platelet volume	rs10512627 (5e-10,22139419)
chr3	132446303	132646303	200001	rs6439371	1e-08	Menarche (age at onset)	rs6439371 (1e-08,21102462)
chr3	136908311	137199311	291001	rs1382269	5e-07	Metabolite levels	rs1382269 (5e-07,19043545)
chr3	142864311	142896311	32001	rs894177	3e-06	Non-alcoholic fatty liver disease histology (other)	rs894177 (3e-06,20708005)
chr3	144169311	144411311	242001	rs800082	3e-06	Smoking behavior	rs800082 (3e-06,19247474)
chr3	144954311	145174311	220001	rs345013	5e-06	Prostate cancer	rs345013 (5e-06,17903305)
chr3	151765198	151904189	138992	rs11712066	3e-21	Infantile hypertrophic pyloric stenosis	rs11712066 (3e-21,23989729);rs11712066 (2e-17,22306654)
chr3	152630311	152746311	116001	rs6785504;rs9883654	2e-06	Response to antineoplastic agents	rs6785504 (7e-06,21659360);rs9883654 (2e-06,21659360)
chr3	153453303	153478303	25001	rs573872	5e-14	Infantile hypertrophic pyloric stenosis	rs573872 (5e-14,23989729);rs573872 (4e-12,22306654)
chr3	156788299	156859299	71001	rs1482853;rs17451107;rs900400;rs7624327;rs13064954	4e-38	Adiposity in newborns;Birth weight;Eating disorders;Diabetic retinopathy 	rs1482853 (6e-21,23575227);rs1482853 (3e-13,23575227);rs1482853 (7e-08,23575227);rs17451107 (1e-06,23575227);rs900400 (4e-38,23202124);rs7624327 (3e-06,22911880);rs13064954 (7e-07,21441570);rs900400 (2e-35,20372150)
chr3	159623299	159702299	79001	rs6799788;rs17810546;rs4680534	4e-28	Major depressive disorder;Behcet's disease;Celiac disease;Multiple sclerosis	rs6799788 (1e-06,23377640);rs17810546 (6e-07,23291587);rs17810546 (4e-28,20190752);rs4680534 (6e-06,19525953);rs17810546 (1e-09,18311140)
chr3	162066307	162384307	318001	rs12493123;rs12636148	2e-06	Reading and spelling;Visceral adipose tissue/subcutaneous adipose tissue ratio	rs12493123 (2e-06,23738518);rs12636148 (5e-06,22589738)
chr3	177067307	177114307	47001	rs12629106	4e-06	Systemic lupus erythematosus	rs12629106 (4e-06,21408207)
chr3	177579307	177704307	125001	rs7612209	4e-06	Cognitive performance	rs7612209 (4e-06,19734545)
chr3	184180307	184219307	39001	rs3930234	8e-06	Alcoholism (alcohol use disorder factor score)	rs3930234 (8e-06,21529783)
chr3	187681299	187758299	77001	rs184662298;rs1553091;rs16862782;rs10937329;rs4686914;rs9820070	9e-30	Serum dimethylarginine levels (asymmetric/symetric ratio);Serum dimethylarginine levels (symmetric);Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin);Myopia (pathological);Renal function-related traits (BUN);Metabolite levels;Hematological and biochemical traits	rs184662298 (3e-06,24159190);rs184662298 (2e-06,24159190);rs1553091 (7e-06,23648065);rs16862782 (5e-07,23049088);rs10937329 (9e-30,22797727);rs4686914 (3e-21,21909109);rs9820070 (1e-11,20139978)
chr3	189391299	189445375	54077	rs17505102	9e-09	Acute lymphoblastic leukemia (childhood)	rs17505102 (2e-08,22076464);rs17505102 (9e-09,22076464)
chr3	191321307	191727307	406001	rs1516489;rs7635839	8e-08	Immune response to smallpox vaccine (IL-6);Response to antipsychotic treatment	rs1516489 (8e-08,22610502);rs7635839 (3e-06,19721433)
chr4	7211038	7249377	38340	rs4234798	5e-10	Insulin-like growth factors	rs4234798 (5e-10,21216879)
chr4	10697732	10814524	116793	rs13142500;rs16872571	2e-10	Rheumatoid arthritis;Myopia (pathological);Vitiligo	rs13142500 (2e-06,24390342);rs13142500 (3e-09,24390342);rs16872571 (2e-10,23049088);rs16872571 (2e-08,22561518)
chr4	13774903	13855903	81001	rs10489087	5e-06	Hemostatic factors and hematological phenotypes	rs10489087 (5e-06,17903294)
chr4	26085017	26135732	50716	rs11933540;rs874040;rs10517086	1e-16	Rheumatoid arthritis;Type 1 diabetes	rs11933540 (1e-16,24390342);rs874040 (4e-07,24449572);rs874040 (1e-16,20453842);rs10517086 (5e-10,19430480)
chr4	29844903	29968903	124001	rs7442317	4e-06	Attention deficit hyperactivity disorder motor coordination	rs7442317 (4e-06,21473668)
chr4	31312732	31404732	92001	rs6448771	5e-09	Lipid traits	rs6448771 (5e-09,22028671)
chr4	34503606	35117606	614001	rs1317830;rs17390445	1e-07	Body mass index (non-asthmatics);Response to antipsychotic treatment	rs1317830 (3e-06,23517042);rs17390445 (1e-07,19721433)
chr4	35402606	35417606	15001	rs1533317	2e-06	QT interval	rs1533317 (2e-06,20031603)
chr4	40291915	40317067	25153	rs6832151	1e-13	Graves' disease	rs6832151 (1e-13,21841780)
chr4	45164636	45186831	22196	rs13130484;rs348495;rs10938397	3e-34	Body mass index;Obesity	rs13130484 (6e-09,23669352);rs348495 (2e-10,23583978);rs10938397 (2e-13,23563607);rs10938397 (3e-34,23563607);rs13130484 (3e-18,23563607);rs13130484 (4e-28,23563607);rs10938397 (4e-31,20935630);rs10938397 (3e-16,19079261)
chr4	55340073	55432073	92001	rs218238;rs218237;rs172629	3e-39	Red blood cell traits;Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell count	rs218238 (3e-39,23222517);rs218237 (3e-25,20139978);rs218237 (2e-29,20139978);rs172629 (1e-27,20139978);rs218237 (2e-17,20139978);rs172629 (1e-15,19862010)
chr4	58949244	59081244	132001	rs10517437	4e-06	Cognitive performance	rs10517437 (4e-06,20125193)
chr4	60469406	60839406	370001	rs10517480	2e-07	Metabolite levels	rs10517480 (2e-07,19043545)
chr4	67614406	68057406	443001	rs1155865	2e-06	Cognitive test performance	rs1155865 (2e-06,17903297)
chr4	80533977	80674977	141001	rs10518224	7e-06	Quantitative traits	rs10518224 (7e-06,19197348)
chr4	88770997	88859130	88134	rs1463104;rs6532023;rs12644436;rs1471403	1e-27	Bone mineral density;HIV-1 viral setpoint;Bone mineral density (hip);Bone mineral density (spine)	rs1463104 (2e-09,24249740);rs6532023 (1e-27,22504420);rs12644436 (6e-06,22174851);rs1471403 (8e-07,19801982);rs1471403 (2e-08,19801982)
chr4	111323397	111394397	71001	rs2087160;rs6825911	7e-13	Metabolic traits;Blood pressure	rs2087160 (7e-13,21886157);rs6825911 (7e-08,21572416);rs6825911 (9e-09,21572416)
chr4	111607314	111735397	128084	rs3853444;rs12646447;rs6843082;rs6817105;rs17042171;rs2200733;rs10033464	2e-74	Coronary heart disease;Ischemic stroke;Stroke (ischemic);Atrial fibrillation;Atrial fibrillation/atrial flutter	rs3853444 (5e-06,24778558);rs12646447 (3e-08,24262325);rs6843082 (2e-07,23041239);rs6843082 (3e-16,23041239);rs6817105 (2e-74,22544366);rs6843082 (3e-28,20173747);rs17042171 (4e-63,19597492);rs2200733 (1e-14,19597491);rs2200733 (2e-10,18991354);rs2200733 (3e-41,17603472);rs10033464 (7e-11,17603472)
chr4	112592397	112769397	177001	rs10034228;rs1585471	8e-13	Myopia (pathological)	rs10034228 (8e-13,21505071);rs1585471 (2e-06,21505071)
chr4	118195553	118401553	206001	rs4318720	8e-07	QT interval	rs4318720 (8e-07,20031603)
chr4	125803551	126002551	199001	rs1986655	2e-06	Bilirubin levels	rs1986655 (2e-06,19414484)
chr4	126889551	127027551	138001	rs1320267	7e-06	Subclinical atherosclerosis traits (other)	rs1320267 (7e-06,17903303)
chr4	131090551	131202551	112001	rs1024020	4e-07	RR interval (heart rate)	rs1024020 (4e-07,20031603)
chr4	135065551	135591551	526001	rs10026364	4e-06	Coronary heart disease	rs10026364 (4e-06,21347282)
chr4	143923396	144032011	108616	rs7686660	2e-12	Asthma	rs7686660 (2e-12,21804548)
chr4	145249274	145516377	267104	rs1980057;rs13141641;rs13118928;rs12504628;rs1828591;rs13147758	3e-20	Pulmonary function (interaction);Chronic obstructive pulmonary disease;Pulmonary function	rs1980057 (5e-18,23284291);rs13141641 (3e-07,22080838);rs13118928 (5e-07,20173748);rs1980057 (3e-20,20010835);rs12504628 (6e-13,20010834);rs1828591 (1e-07,19300482);rs13147758 (8e-11,19300500)
chr4	149540551	149734396	193846	rs10032216;rs10028213;rs10519980;rs2358462	9e-16	Thyroid hormone levels;Thyroid function;Hypothyroidism;Non-alcoholic fatty liver disease histology (other)	rs10032216 (9e-16,23408906);rs10032216 (2e-13,23408906);rs10028213 (3e-10,22494929);rs10519980 (7e-06,22493691);rs2358462 (4e-06,20708005)
chr4	161309030	161730551	421522	rs17291045	5e-08	HIV-1 control	rs17291045 (5e-08,20041166)
chr4	180015007	180160007	145001	rs17067123	8e-06	Response to hepatitis C treatment	rs17067123 (8e-06,19684573)
chr5	1890876	1901001	10126	rs12653946	4e-18	Prostate cancer	rs12653946 (3e-07,22923026);rs12653946 (4e-18,20676098)
chr5	3992001	4102001	110001	rs11748327	5e-13	Myocardial infarction	rs11748327 (5e-13,21107343)
chr5	5768001	5801001	33001	rs32566	2e-09	Morbidity-free survival	rs32566 (2e-09,17903295)
chr5	5827001	5915001	88001	rs7728043	1e-06	QT interval	rs7728043 (1e-06,20031603)
chr5	6758001	6841001	83001	rs275456;rs12520016;rs1566039;rs11134178	1e-08	Paclitaxel-induced neuropathy;Eye color;Sphingolipid levels;Attention deficit hyperactivity disorder	rs275456 (3e-06,23776197);rs12520016 (9e-07,23548203);rs1566039 (1e-08,22359512);rs11134178 (3e-06,18821564)
chr5	7184001	7272001	88001	rs4537030;rs7729273	7e-07	Mean arterial pressure (alcohol consumption interaction);Cognitive performance	rs4537030 (7e-07,24376456);rs7729273 (1e-06,19734545)
chr5	25719244	26124244	405001	rs396045;rs7727656;rs10038113;rs4307059	2e-10	Obesity-related traits;Hippocampal atrophy;Autism	rs396045 (7e-06,23251661);rs7727656 (8e-06,19668339);rs10038113 (3e-06,19456320);rs4307059 (2e-10,19404256)
chr5	28720244	28769244	49001	rs2548003	2e-07	Hip geometry	rs2548003 (2e-07,17903296)
chr5	31017244	31059475	42232	rs6888304	1e-09	Liver enzyme levels (gamma-glutamyl transferase)	rs6888304 (1e-09,22001757)
chr5	36472244	36540244	68001	rs2937550	8e-06	IgG glycosylation;Height	rs2937550 (9e-06,23382691);rs2937550 (8e-06,21998595)
chr5	40089244	40184244	95001	rs2548145	2e-06	Alcoholism (alcohol use disorder factor score)	rs2548145 (2e-06,21529783)
chr5	40286244	40551044	264801	rs7720838;rs11742570;rs9292777;rs4613763;rs10440635;rs6451493;rs6896969;rs1992660;rs17234657;rs1373692	2e-82	Self-reported allergy;Inflammatory bowel disease;Crohn's disease;Multiple sclerosis;Ankylosing spondylitis;Ulcerative colitis	rs7720838 (8e-11,23817569);rs11742570 (2e-82,23128233);rs11742570 (1e-06,22936669);rs9292777 (1e-09,22570697);rs9292777 (2e-11,22412388);rs4613763 (3e-16,21833088);rs10440635 (3e-07,21743469);rs6451493 (3e-09,21297633);rs11742570 (7e-36,21102463);rs6896969 (2e-07,19525953);rs4613763 (7e-27,18587394);rs1992660 (4e-07,17684544);rs17234657 (2e-12,17554300);rs9292777 (3e-18,17554261);rs1373692 (2e-12,17447842)
chr5	57201244	57340244	139001	rs1844437	2e-06	Hoarding	rs1844437 (2e-06,21302353)
chr5	58406244	58409244	3001	rs10052657	2e-19	Esophageal cancer	rs10052657 (2e-19,21642993)
chr5	83153245	83223245	70001	rs4552569	9e-10	Ankylosing spondylitis	rs4552569 (9e-10,22138694)
chr5	84397245	85047245	650001	rs12153606;rs4920799	2e-06	Blood trace element (Cu levels);Echocardiographic traits	rs12153606 (2e-06,23720494);rs4920799 (7e-06,17903301)
chr5	88269848	88440245	170398	rs6894139;rs1366594;rs10037512	4e-61	Bone mineral density;Height;Bone mineral density (hip)	rs6894139 (7e-18,24249740);rs1366594 (4e-61,22504420);rs1366594 (8e-10,21533022);rs1366594 (1e-07,21533022);rs10037512 (2e-18,20881960);rs1366594 (1e-13,19801982)
chr5	91838245	91953245	115001	rs1027643	5e-10	Wilms tumor	rs1027643 (5e-10,22544364)
chr5	100594102	101096102	502001	rs13188771	2e-06	Conduct disorder (interaction)	rs13188771 (2e-06,18846501)
chr5	104853102	105216154	363053	rs7447447;rs10479334	2e-09	Caffeine consumption;Personality dimensions	rs7447447 (7e-06,21490707);rs10479334 (2e-09,21368711)
chr5	107816102	107938102	122001	rs10447248;rs4571457	5e-08	Adiponectin levels;Ulcerative colitis	rs10447248 (5e-08,21700879);rs4571457 (7e-06,20848476)
chr5	109422102	109497102	75001	rs4460176	3e-06	Hemostatic factors and hematological phenotypes	rs4460176 (3e-06,17903294)
chr5	110400102	110403102	3001	rs1837253	1e-16	Asthma and hay fever;Asthma	rs1837253 (1e-09,24388013);rs1837253 (1e-16,21804548);rs1837253 (1e-14,21804549)
chr5	113011102	113122102	111001	rs4621553	4e-08	Sudden cardiac arrest	rs4621553 (4e-08,21658281)
chr5	124317102	124358883	41782	rs3936060;rs4836133	2e-09	Body mass index	rs3936060 (5e-06,23669352);rs4836133 (2e-09,20935630)
chr5	124679102	124854102	175001	rs17468244;rs2637496	8e-06	Obesity-related traits;HIV-1 control	rs17468244 (8e-06,23251661);rs2637496 (9e-06,20041166)
chr5	134412102	134470102	58001	rs254560;rs477687	1e-09	Ulcerative colitis;AIDS progression	rs254560 (3e-09,23128233);rs477687 (6e-06,21502085);rs254560 (1e-09,21297633)
chr5	141862817	141971817	109001	rs152439;rs17577085	4e-06	PR interval in Tripanosoma cruzi seropositivity;Coronary heart disease	rs152439 (4e-06,24324551);rs17577085 (4e-06,21347282)
chr5	142892808	143016808	124001	rs12153243;rs17100498	5e-07	Migraine;Response to antipsychotic treatment	rs12153243 (6e-06,23793025);rs17100498 (5e-07,20195266)
chr5	144941808	145083808	142001	rs10515552	4e-08	Vitamin B12 levels	rs10515552 (4e-08,22367966)
chr5	157728994	157892731	163738	rs74620148;rs11953630;rs9313772	4e-13	PR interval in Tripanosoma cruzi seropositivity;Diastolic blood pressure;Hypertension;Systolic blood pressure;Blood pressure	rs74620148 (6e-06,24324551);rs11953630 (4e-13,21909115);rs11953630 (2e-07,21909115);rs11953630 (3e-11,21909115);rs9313772 (1e-11,21909110)
chr5	158824423	158860635	36213	rs6871626;rs12188300	1e-42	Inflammatory bowel disease;Ulcerative colitis;Psoriatic arthritis	rs6871626 (1e-42,23128233);rs6871626 (1e-21,21297633);rs12188300 (7e-17,20953186)
chr5	163853423	163992423	139001	rs6556756	5e-07	Breast cancer	rs6556756 (5e-07,17903305)
chr5	165028423	165082423	54001	rs958994	8e-06	Carotid atherosclerosis in HIV infection	rs958994 (8e-06,20009918)
chr5	165314423	165514423	200001	rs9313296	7e-07	Waist circumference;Weight	rs9313296 (6e-06,20966902);rs9313296 (7e-07,20966902)
chr5	165943423	166066423	123001	rs2122554	3e-06	Conduct disorder (symptom count)	rs2122554 (3e-06,20585324)
chr5	171074396	171103396	29001	rs254893	6e-06	Quantitative traits	rs254893 (6e-06,19197348)
chr5	172864395	173004395	140001	rs6869841;rs889014;rs7722022	9e-16	Prostate cancer;Height;Adiponectin levels	rs6869841 (5e-08,23535732);rs889014 (9e-16,20881960);rs7722022 (9e-06,19165155)
chr6	446092	472001	25910	rs12202284;rs1540771	4e-18	Non-melanoma skin cancer;Freckles	rs12202284 (5e-08,23548203);rs1540771 (4e-18,17952075)
chr6	6730511	6761002	30492	rs1294410;rs1294421	2e-10	Waist-hip ratio	rs1294410 (1e-06,23966867);rs1294421 (2e-10,23563607)
chr6	9409015	9522015	113001	rs10484246	8e-08	Morbidity-free survival	rs10484246 (8e-08,17903295)
chr6	10112015	10244015	132001	rs12210761;rs13195786	6e-06	Major depressive disorder;Calcium levels	rs12210761 (6e-06,23377640);rs13195786 (7e-06,20705733)
chr6	12187015	12204015	17001	rs1040994	2e-06	Response to antipsychotic treatment	rs1040994 (2e-06,19721433)
chr6	14162022	14278022	116001	rs7758616;rs853356	3e-06	Obesity-related traits;Height	rs7758616 (4e-06,23251661);rs853356 (3e-06,21998595)
chr6	14513022	14622022	109001	rs9296949;rs12213875;rs7770731;rs6914079	3e-07	Metabolite levels (HVA/MHPG ratio);Ovarian reserve;Response to antipsychotic treatment in schizophrenia (working memory);Cognitive test performance	rs9296949 (2e-06,23319000);rs12213875 (3e-07,22116950);rs7770731 (1e-06,21107309);rs6914079 (2e-06,17903297)
chr6	16156139	16204022	47884	rs6924995;rs2142672	2e-08	Response to statin therapy (LDL-C);LDL cholesterol	rs6924995 (5e-07,22331829);rs2142672 (2e-08,20864672)
chr6	20652716	20733022	80307	rs7754840;rs6931514;rs7766070;rs2206734;rs9356744;rs7747752;rs9295474;rs6908425;rs10440833;rs4712523;rs10946398;rs4712524;rs9465871;rs7756992	2e-22	Type 2 diabetes;Birth weight;Body mass index;Glycated hemoglobin levels;Diabetes (gestational);Ileal carcinoids;Crohn's disease;Type 2 diabetes and other traits	rs7754840 (2e-13,23945395);rs6931514 (2e-18,23202124);rs7754840 (7e-10,22961080);rs7766070 (7e-10,22693455);rs7766070 (6e-11,22693455);rs2206734 (1e-11,22344221);rs9356744 (2e-11,22344219);rs7747752 (1e-11,22290723);rs7754840 (7e-16,22233651);rs9295474 (9e-06,21490949);rs2206734 (8e-06,21139019);rs6908425 (1e-08,21102463);rs10440833 (2e-22,20581827);rs4712523 (2e-12,19734900);rs4712523 (7e-20,19401414);rs10946398 (7e-07,19056611);rs4712524 (3e-10,18711366);rs6908425 (9e-10,18587394);rs6931514 (1e-11,18372903);rs9465871 (3e-07,17554300);rs7754840 (4e-11,17463246);rs7754840 (4e-11,17463248);rs7756992 (8e-09,17460697);rs10946398 (1e-08,17463249)
chr6	21311022	21393733	82712	rs9466056	3e-13	Bone mineral density	rs9466056 (3e-13,22504420);rs9466056 (4e-06,21533022)
chr6	22623022	22749022	126001	rs4712709;rs10498712	6e-06	Metabolite levels (Pyroglutamine);Quantitative traits	rs4712709 (6e-06,23934736);rs10498712 (9e-06,19197348)
chr6	33813042	33822023	8982	rs4713693	7e-13	Graves' disease	rs4713693 (7e-13,21900946)
chr6	40776023	40823023	47001	rs10484761	7e-12	Esophageal cancer	rs10484761 (7e-12,21642993)
chr6	43782023	43835023	53001	rs943080;rs9472138;rs729761;rs4711751;rs943072;rs881858	7e-16	Age-related macular degeneration;Thyroid hormone levels;Urate levels;Ulcerative colitis;Chronic kidney disease;Type 2 diabetes	rs943080 (9e-16,23455636);rs9472138 (7e-16,23408906);rs9472138 (6e-12,23408906);rs9472138 (5e-06,23408906);rs729761 (8e-16,23263486);rs4711751 (9e-09,21665990);rs943072 (2e-10,21297633);rs881858 (9e-14,20383146);rs9472138 (4e-06,18372903)
chr6	43875023	43918023	43001	rs11755845 ;rs9472155	2e-26	Thyroid hormone levels;Vascular endothelial growth factor levels	rs11755845  (2e-10,23408906);rs11755845  (3e-07,23408906);rs9472155 (2e-26,21757650)
chr6	50942042	51102042	160001	rs7775861;rs7762246;rs190759;rs283566	9e-08	Body mass index (non-asthmatics);Obesity-related traits;Sudden cardiac arrest;Electrocardiographic conduction measures	rs7775861 (9e-08,23517042);rs7762246 (6e-06,23251661);rs190759 (5e-06,21658281);rs283566 (9e-06,19389651)
chr6	67630280	67720280	90001	rs28631020;rs11970254	6e-07	Bulimia nervosa;Brain structure	rs28631020 (3e-06,23568457);rs11970254 (6e-07,20171287)
chr6	88554282	88656282	102001	rs2509458	7e-06	Blood pressure	rs2509458 (7e-06,17903302)
chr6	88974282	89050282	76001	rs16880441	9e-06	Conduct disorder (interaction)	rs16880441 (9e-06,18846501)
chr6	89086282	89173282	87001	rs10485165	1e-06	Select biomarker traits	rs10485165 (1e-06,17903293)
chr6	91123280	91210280	87001	rs806276	3e-07	Attention deficit hyperactivity disorder (time to onset)	rs806276 (3e-07,18937294)
chr6	91401280	91489280	88001	rs713155	5e-07	Brain structure	rs713155 (5e-07,20171287)
chr6	98346280	98800280	454001	rs9320913;rs2505059;rs9375225;rs12529874 ;rs6909430	4e-10	Educational attainment;Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs);QT interval (interaction);Oleic acid (18:1n-9) plasma levels;Quantitative traits	rs9320913 (4e-10,23722424);rs2505059 (5e-06,23648065);rs9375225 (6e-06,23459443);rs12529874  (3e-07,23362303);rs6909430 (8e-06,19197348)
chr6	99533280	99674280	141001	rs2132683	1e-06	Brain structure	rs2132683 (1e-06,20171287)
chr6	100113280	100290280	177001	rs4840086	2e-08	Menarche (age at onset)	rs4840086 (2e-08,21102462)
chr6	106058308	106123308	65001	rs9386463	6e-07	Primary tooth development (time to first tooth eruption)	rs9386463 (6e-07,20195514)
chr6	106406308	106503691	97384	rs6568421;rs7746082	8e-20	Inflammatory bowel disease;Crohn's disease	rs6568421 (8e-20,23128233);rs6568421 (4e-08,21102463);rs7746082 (2e-10,18587394)
chr6	106507308	106533308	26001	rs6911490	1e-08	Ulcerative colitis	rs6911490 (1e-08,21297633)
chr6	106885308	106922308	37001	rs1417352	2e-06	Select biomarker traits	rs1417352 (2e-06,17903293)
chr6	121081302	121220302	139001	rs2789066;rs2817937	3e-06	HIV-1 viral setpoint;Primary tooth development (number of teeth)	rs2789066 (9e-06,20205591);rs2817937 (3e-06,20195514)
chr6	121899302	122198302	299001	rs1015451;rs9320841;rs9398652;rs12110693;rs4541776	1e-33	Heart rate;Resting heart rate;Biomedical quantitative traits;Protein quantitative trait loci	rs1015451 (1e-33,23583979);rs9320841 (5e-15,23183192);rs9398652 (4e-15,20639392);rs12110693 (2e-09,19396169);rs4541776 (2e-06,18464913)
chr6	134737308	134806308	69001	rs9321453	1e-09	Urate levels	rs9321453 (1e-09,21768215)
chr6	136015886	136146308	130423	rs947583	3e-12	Phosphorus levels	rs947583 (3e-12,20558539)
chr6	137956308	138025308	69001	rs6920220;rs13192841;rs2327832;rs10499194	1e-21	Rheumatoid arthritis;Inflammatory bowel disease;Multiple sclerosis;Ulcerative colitis;Celiac disease	rs6920220 (3e-08,24449572);rs6920220 (1e-21,23128233);rs13192841 (1e-08,21833088);rs6920220 (8e-17,21297633);rs6920220 (9e-13,20453842);rs2327832 (4e-19,20190752);rs6920220 (2e-09,18794853);rs10499194 (1e-09,17982456);rs6920220 (1e-07,17982456)
chr6	139826308	139847308	21001	rs605066;rs679582;rs668459;rs590856;rs592423;rs632057;rs628751;rs643381	5e-36	HDL cholesterol;Blood trace element (Se levels);Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell traits;Adiponectin levels	rs605066 (3e-08,24097068);rs679582 (3e-06,23720494);rs668459 (9e-09,23263863);rs668459 (4e-08,23263863);rs590856 (5e-36,23222517);rs668459 (3e-06,22479202);rs592423 (4e-07,22479202);rs605066 (3e-08,20686565);rs632057 (1e-09,20139978);rs628751 (1e-17,19862010);rs643381 (5e-25,19862010)
chr6	140195308	141054308	859001	rs642858	2e-06	Type 2 diabetes	rs642858 (2e-06,21490949)
chr6	149492308	149612308	120001	rs9485372;rs636864;rs727979	4e-12	Breast cancer;Hemostatic factors and hematological phenotypes	rs9485372 (4e-12,22383897);rs636864 (6e-06,17903294);rs727979 (8e-06,17903294)
chr6	152052310	152111887	59578	rs60945108;rs543650;rs2504063;rs1999805	1e-17	Obesity-related traits;Height;Bone mineral density (spine)	rs60945108 (3e-06,23251661);rs543650 (1e-17,20881960);rs2504063 (6e-11,19801982);rs1999805 (2e-08,18445777)
chr6	159470057	159517592	47536	rs2451258;rs212388	3e-14	Rheumatoid arthritis;Crohn's disease;Crohn's disease and celiac disease	rs2451258 (3e-11,24390342);rs2451258 (2e-10,24390342);rs212388 (3e-14,23128233);rs212388 (2e-10,21298027);rs212388 (2e-11,21102463)
chr6	166138590	166198590	60001	rs1039002	2e-08	Bipolar disorder	rs1039002 (2e-08,22205951)
chr6	170368704	170445369	76666	rs10946292;rs924043	8e-09	Obesity-related traits;Type 1 diabetes	rs10946292 (3e-06,23251661);rs924043 (8e-09,21980299)
chr7	4380475	4458475	78001	rs10488360	7e-06	Factor VII	rs10488360 (7e-06,17903294)
chr7	8971476	9006476	35001	rs17157663	9e-06	Quantitative traits	rs17157663 (9e-06,19197348)
chr7	9500476	9705476	205001	rs12702919;rs9918508	5e-06	PR interval in Tripanosoma cruzi seropositivity;Hippocampal atrophy	rs12702919 (5e-06,24324551);rs9918508 (8e-06,19668339)
chr7	12905476	12996476	91001	rs732577;rs17166499	4e-06	Sudden cardiac arrest;Bipolar disorder and schizophrenia	rs732577 (4e-06,21658281);rs17166499 (5e-06,20889312)
chr7	15016941	15068761	51821	rs2191349;rs6947830;rs10244051	3e-44	Fasting glucose-related traits (interaction with BMI);Metabolic syndrome;Fasting glucose-related traits;Metabolic traits	rs2191349 (3e-21,22581228);rs6947830 (1e-13,22399527);rs2191349 (3e-44,20081858);rs2191349 (3e-17,20081858);rs10244051 (1e-07,19060910)
chr7	17277761	17330117	52357	rs13236243;rs12670403;rs4410790;rs6968865	2e-19	Sensory disturbances after bilateral sagittal split ramus osteotomy;Metabolic traits;Caffeine consumption;Coffee consumption	rs13236243 (4e-06,23834954);rs12670403 (5e-15,21886157);rs4410790 (2e-19,21490707);rs6968865 (2e-11,21357676)
chr7	17517476	17618476	101001	rs10499504	4e-07	Response to antipsychotic treatment	rs10499504 (4e-07,20195266)
chr7	19550835	19658761	107927	rs4470914	9e-10	Height	rs4470914 (9e-10,20881960)
chr7	25487476	25716476	229001	rs975369;rs17151904	1e-06	Preeclampsia;Carotid atherosclerosis in HIV infection	rs975369 (8e-06,23551011);rs17151904 (1e-06,20009918)
chr7	25843761	25936476	92716	rs12700667;rs1055144	1e-24	Endometriosis;Waist-hip ratio	rs12700667 (4e-09,23104006);rs12700667 (1e-09,21151130);rs1055144 (1e-24,20935629)
chr7	35531761	35561869	30109	rs343064	3e-08	Non-alcoholic fatty liver disease histology (other)	rs343064 (3e-08,20708005)
chr7	38074372	38167761	93390	rs6959212;rs1524058	4e-38	Bone mineral density;Height;Bone mineral density (spine)	rs6959212 (4e-38,22504420);rs6959212 (2e-09,20881960);rs1524058 (1e-09,19801982)
chr7	41462761	41480761	18001	rs1079866;rs10486715	6e-14	Menarche (age at onset);Quantitative traits	rs1079866 (6e-14,21102462);rs10486715 (3e-06,19197348)
chr7	46121476	46366476	245001	rs6964415;rs1486139	5e-07	Sudden cardiac arrest;Select biomarker traits	rs6964415 (5e-07,21658281);rs1486139 (2e-06,17903293)
chr7	46606761	46708761	102001	rs7784776	1e-09	QRS duration	rs7784776 (1e-09,21076409)
chr7	50253740	50335740	82001	rs4917014;rs17664743;rs4917017;rs10276619;rs1456896;rs1456893	3e-23	HDL cholesterol;Self-reported allergy;IgG glycosylation;Systemic lupus erythematosus;Inflammatory bowel disease;Crohn's disease;Hippocampal atrophy	rs4917014 (1e-08,24097068);rs17664743 (5e-06,23817569);rs4917017 (2e-07,23382691);rs4917017 (1e-08,23382691);rs10276619 (6e-06,23273568);rs1456896 (7e-15,23128233);rs1456896 (1e-08,21102463);rs4917014 (3e-23,19838193);rs10276619 (3e-06,19668339);rs1456893 (5e-09,18587394)
chr7	50898792	51082792	184001	rs4948088	4e-08	Type 1 diabetes	rs4948088 (4e-08,19430480)
chr7	54072507	54220507	148001	rs6593122	4e-06	Vaccine-related adverse events 	rs6593122 (4e-06,21396408)
chr7	66951566	67153566	202001	rs10263639	3e-06	Breast cancer	rs10263639 (3e-06,17903305)
chr7	106302050	106469050	167001	rs342293;rs342296;rs342275;rs17398575;rs17477177	7e-57	Mean platelet volume;Platelet counts;Carotid intima media thickness;Blood pressure	rs342293 (5e-22,24026423);rs342293 (2e-08,22423221);rs342296 (1e-11,22423221);rs342293 (7e-57,22139419);rs342275 (6e-25,22139419);rs17398575 (2e-12,21909108);rs17398575 (3e-06,21909108);rs17477177 (2e-13,21909110);rs342293 (2e-33,19820697);rs342293 (1e-24,19221038)
chr7	107777050	107784050	7001	rs382140	4e-09	Coffee consumption	rs382140 (4e-09,21876539)
chr7	108522765	108667765	145001	rs1404697;rs848353	3e-07	Smoking behavior	rs1404697 (8e-06,22006218);rs1404697 (5e-06,22006218);rs848353 (2e-06,22006218);rs848353 (9e-07,22006218);rs848353 (3e-07,22006218)
chr7	130420746	130468189	47444	rs4731702;rs972283	5e-17	HDL cholesterol;Type 2 diabetes	rs4731702 (5e-17,24097068);rs4731702 (1e-15,20686565);rs972283 (2e-10,20581827)
chr7	131328461	131414461	86001	rs11761231	4e-07	Rheumatoid arthritis	rs11761231 (4e-07,17554300)
chr7	131441461	131484461	43001	rs1106683;rs1106684	1e-07	Body mass index	rs1106683 (1e-07,17903300);rs1106684 (2e-06,17903300)
chr7	151389353	151423195	33843	rs10480300;rs7805747;rs10224002	3e-15	Urate levels;Red blood cell traits;Chronic kidney disease;Hematocrit;Hemoglobin	rs10480300 (4e-09,23263486);rs10480300 (8e-15,23222517);rs7805747 (4e-12,20383146);rs10224002 (6e-15,19862010);rs10224002 (3e-15,19862010)
chr7	154207041	154220821	13781	rs10260404	5e-08	Amyotrophic lateral sclerosis	rs10260404 (3e-06,18987618);rs10260404 (5e-08,18084291);rs10260404 (3e-06,18057069)
chr8	5460593	5494593	34001	rs4875598	9e-06	Attention deficit hyperactivity disorder symptoms (interaction)	rs4875598 (9e-06,18846501)
chr8	9165591	9247591	82001	rs9987289;rs4841132;rs1461729;rs2126259;rs6984305;rs6601299	2e-41	Cholesterol, total;HDL cholesterol;LDL cholesterol;Glycemic traits (pregnancy);Metabolite levels;Fasting glucose-related traits (interaction with BMI);Fasting insulin-related traits (interaction with BMI);Liver enzyme levels (alkaline phosphatase);HDL Cholesterol - Triglycerides (HDLC-TG);Metabolic syndrome (bivariate traits);Coronary heart disease;C-reactive protein	rs9987289 (2e-36,24097068);rs9987289 (2e-41,24097068);rs9987289 (9e-24,24097068);rs4841132 (5e-15,23903356);rs4841132 (3e-13,23903356);rs1461729 (7e-09,23726366);rs2126259 (1e-06,23505323);rs4841132 (2e-09,22916037);rs4841132 (8e-09,22581228);rs4841132 (2e-10,22581228);rs6984305 (2e-10,22001757);rs9987289 (1e-08,21386085);rs9987289 (4e-08,21386085);rs6601299 (1e-08,21347282);rs9987289 (3e-13,21300955);rs2126259 (7e-12,20864672);rs9987289 (9e-24,20686565);rs9987289 (6e-25,20686565);rs9987289 (7e-15,20686565)
chr8	12616630	12714630	98001	rs17120471;rs4831837	5e-07	IgG glycosylation;Morbidity-free survival	rs17120471 (6e-06,23382691);rs4831837 (5e-07,17903295)
chr8	29325082	29404082	79001	rs12548021;rs10091038	3e-08	Colorectal cancer;Response to statin therapy	rs12548021 (3e-06,23350875);rs10091038 (3e-08,20339536)
chr8	33534459	34081654	547196	rs9297216;rs10503951;rs11786194;rs4469412	3e-09	Asthma (childhood onset);Immune response to smallpox vaccine (IL-6)	rs9297216 (1e-06,23829686);rs10503951 (3e-09,22542470);rs11786194 (9e-07,22542470);rs4469412 (9e-07,22542470)
chr8	40449678	40517617	67940	rs2722425	2e-08	Fasting plasma glucose	rs2722425 (2e-08,17903298);rs2722425 (9e-06,17903298)
chr8	49039448	49282448	243001	rs11778329	7e-06	Attention deficit hyperactivity disorder	rs11778329 (7e-06,21784300)
chr8	54395448	54450448	55001	rs10958369	2e-06	Response to antineoplastic agents	rs10958369 (2e-06,21659360)
chr8	55281448	55331127	49680	rs1504749;rs10958409	1e-10	Intracranial aneurysm	rs1504749 (5e-07,20364137);rs10958409 (1e-10,18997786)
chr8	69947984	70007447	59464	rs2912522	2e-13	Dupuytren's disease	rs2912522 (2e-13,21732829)
chr8	73040447	73169447	129001	rs11994034;rs1963982	3e-06	Attention deficit hyperactivity disorder (combined symptoms);Blood pressure	rs11994034 (7e-06,23527680);rs1963982 (3e-06,17903302)
chr8	78014446	78257161	242716	rs7821178;rs6473015;rs7846385	7e-13	Menarche (age at onset);Height	rs7821178 (3e-09,21102462);rs6473015 (7e-13,20881960);rs7846385 (5e-08,18391951)
chr8	83785446	83998446	213001	rs7015622;rs1375785	1e-06	Response to antidepressant treatment;Information processing speed	rs7015622 (1e-06,22041458);rs1375785 (8e-06,21130836)
chr8	101763825	101858825	95001	rs36061340;rs3847153;rs3108919	9e-08	Alcohol consumption;Premature ovarian failure;AIDS	rs36061340 (7e-06,23743675);rs3847153 (9e-08,21989058);rs3108919 (4e-06,19754311)
chr8	105983825	106035825	52001	rs977396	3e-07	Response to antipsychotic treatment	rs977396 (3e-07,20195266)
chr8	108767825	108815825	48001	rs4534106	1e-06	Brain structure	rs4534106 (1e-06,20171287)
chr8	109591825	109666825	75001	rs2935776	6e-07	Cerebrospinal T-tau levels	rs2935776 (6e-07,20932310)
chr8	116356825	116406825	50001	rs17658378	9e-06	Attention deficit hyperactivity disorder (time to onset)	rs17658378 (9e-06,18937294)
chr8	117475820	117590820	115001	rs4876662	2e-06	Aortic root size	rs4876662 (2e-06,21223598)
chr8	117616700	117642989	26290	rs11987235;rs16892766	3e-18	Corneal curvature;Colorectal cancer	rs11987235 (7e-06,22969067);rs16892766 (4e-07,21761138);rs16892766 (3e-18,18372905)
chr8	122888820	123030820	142001	rs956225;rs907121;rs7844723	2e-06	Alzheimer's disease;Weight;Hemostatic factors and hematological phenotypes	rs956225 (9e-06,22159054);rs907121 (2e-06,20966902);rs7844723 (2e-06,17903294)
chr8	123220408	123443094	222687	rs11781551	2e-11	Carotid intima media thickness	rs11781551 (2e-11,21909108)
chr8	126456375	126513819	57445	rs17321515;rs2954029;rs2980879;rs2954021;rs2001945;rs2954026;rs2954033;rs2954038;rs6982636;rs6987702	1e-107	Lipid traits;Cholesterol, total;HDL cholesterol;LDL cholesterol;Triglycerides;Adiponectin levels;Liver enzyme levels (alanine transaminase);Liver enzyme levels (alkaline phosphatase);HDL Cholesterol - Triglycerides (HDLC-TG);Triglycerides-Blood Pressure (TG-BP);Response to statin therapy;Lipid metabolism phenotypes	rs17321515 (8e-07,24386095);rs2954029 (2e-65,24097068);rs2954029 (3e-29,24097068);rs2954029 (2e-50,24097068);rs2954029 (1e-107,24097068);rs2980879 (7e-09,22479202);rs2980879 (1e-09,22479202);rs2954021 (5e-09,22001757);rs2954021 (2e-13,22001757);rs2001945 (1e-20,21909109);rs2954026 (8e-09,21386085);rs2954033 (9e-09,21386085);rs2954021 (1e-07,20864672);rs2954029 (2e-11,20864672);rs2954029 (5e-36,20686565);rs2954029 (6e-19,20686565);rs2954029 (3e-29,20686565);rs2954029 (3e-55,20686565);rs2954038 (7e-06,20339536);rs2954029 (3e-07,20139978);rs6982636 (7e-12,19936222);rs6982636 (1e-09,19936222);rs6987702 (3e-09,19060911);rs6987702 (3e-06,19060911);rs2954029 (3e-19,19060906);rs17321515 (4e-17,18193044);rs17321515 (7e-13,18193043)
chr8	126523819	126545819	22001	rs921720;rs4871611;rs1551398	8e-20	Obesity-related traits;Inflammatory bowel disease;Crohn's disease	rs921720 (3e-06,23251661);rs921720 (8e-20,23128233);rs4871611 (2e-12,21102463);rs1551398 (5e-09,18587394)
chr8	128069819	128235819	166001	rs2466024;rs1456315;rs6983561;rs10505483;rs13254738;rs13252298;rs1016343;rs16901979	2e-29	Chronic lymphocytic leukemia;Prostate cancer	rs2466024 (3e-06,24292274);rs1456315 (1e-12,23023329);rs6983561 (4e-13,22923026);rs10505483 (7e-15,22923026);rs13254738 (4e-10,22923026);rs13252298 (4e-06,21743057);rs1016343 (4e-10,21743057);rs1456315 (2e-29,20676098);rs16901979 (3e-14,19767754);rs1016343 (1e-07,18264097);rs16901979 (1e-12,17401366)
chr8	128303819	128407819	104001	rs13281615;rs445114;rs1562430;rs16902094;rs10505477	1e-27	Breast cancer;Prostate cancer;Colorectal cancer	rs13281615 (1e-27,23535729);rs445114 (5e-07,21743057);rs1562430 (3e-11,21263130);rs1562430 (6e-07,20453838);rs445114 (5e-10,19767754);rs16902094 (6e-15,19767754);rs10505477 (3e-11,17618283);rs13281615 (5e-12,17529967)
chr8	128466819	128550819	84001	rs10090154;rs17766217;rs4242384;rs7837688;rs1447295;rs4242382	1e-25	Prostate cancer;Response to antidepressant treatment	rs10090154 (3e-06,22923026);rs17766217 (3e-07,22041458);rs4242384 (3e-16,21743057);rs7837688 (1e-25,20676098);rs4242384 (2e-24,19767753);rs1447295 (2e-19,19767754);rs4242384 (3e-16,18264097);rs4242382 (3e-19,18264096);rs1447295 (6e-18,17401366);rs1447295 (2e-14,17401363)
chr8	128713664	128726313	12650	rs9642880	4e-38	Bladder cancer;Urinary bladder cancer	rs9642880 (4e-38,24163127);rs9642880 (2e-18,20972438);rs9642880 (7e-12,20348956);rs9642880 (9e-12,18794855)
chr8	129116819	129299819	183001	rs2019960;rs11775199;rs11780156;rs11995854;rs10492294;rs9792269	1e-13	Hodgkin's lymphoma;Metabolite levels (Dihydroxy docosatrienoic acid);Breast cancer;Obesity-related traits;Multiple sclerosis;Immunoglobulin A ;Celiac disease	rs2019960 (6e-10,24149102);rs11775199 (7e-06,23934736);rs11780156 (3e-11,23535729);rs11995854 (8e-06,23251661);rs2019960 (5e-09,21833088);rs2019960 (1e-13,21037568);rs10492294 (4e-06,20694011);rs9792269 (3e-09,20190752)
chr8	129307819	129597819	290001	rs1516971;rs10088218;rs6651252;rs7815944;rs975730	4e-18	Rheumatoid arthritis;Ovarian cancer;Crohn's disease;Atopic dermatitis;Celiac disease and Rheumatoid arthritis	rs1516971 (3e-11,24390342);rs1516971 (1e-10,24390342);rs10088218 (3e-12,23535730);rs10088218 (1e-17,23535730);rs6651252 (1e-16,23128233);rs7815944 (4e-07,23042114);rs975730 (2e-08,21383967);rs6651252 (4e-18,21102463);rs10088218 (3e-09,20852632)
chr8	129797819	130003819	206001	rs987525	5e-35	Orofacial clefts;Cleft lip	rs987525 (5e-35,22863734);rs987525 (1e-26,22863734);rs987525 (2e-11,22863734);rs987525 (4e-16,20436469);rs987525 (9e-08,19656524);rs987525 (3e-24,19270707)
chr8	130458819	130524451	65633	rs891835	8e-11	Glioma	rs891835 (8e-11,19578367)
chr8	130569892	130698819	128928	rs9918807;rs1991866;rs10098310;rs10956483;rs4295627	5e-21	Retinopathy in non-diabetics;Inflammatory bowel disease;White blood cell count;White blood cell types;Glioma	rs9918807 (5e-06,23393555);rs1991866 (2e-09,23128233);rs10098310 (3e-20,21738480);rs10956483 (2e-10,21738478);rs4295627 (5e-21,21531791);rs4295627 (2e-18,19578367)
chr8	136688819	136768819	80001	rs4243849	2e-06	Non-alcoholic fatty liver disease histology (other)	rs4243849 (2e-06,20708005)
chr8	136869819	136958819	89001	rs12680546	3e-06	Amyotrophic lateral sclerosis	rs12680546 (3e-06,17362836)
chr8	142089290	142106819	17530	rs4961252	3e-08	Response to interferon beta therapy	rs4961252 (3e-08,21502966)
chr9	858734	884001	25268	rs755383	2e-26	Testicular germ cell tumor;Testicular cancer;Testicular germ cell cancer	rs755383 (4e-07,23666239);rs755383 (2e-26,23666240);rs755383 (9e-10,21551455);rs755383 (1e-23,20543847)
chr9	1196001	1238305	42305	rs10809650	6e-09	Dupuytren's disease	rs10809650 (6e-09,21732829)
chr9	2672808	2698001	25194	rs930811;rs10738760	1e-39	Obesity-related traits;Vascular endothelial growth factor levels	rs930811 (1e-06,23251661);rs10738760 (1e-39,21757650)
chr9	4746362	4766001	19640	rs385893	9e-17	Platelet counts;Hematological parameters	rs385893 (3e-13,20139978);rs385893 (9e-17,19820697)
chr9	9194001	9386909	192909	rs4626664	6e-10	Restless legs syndrome	rs4626664 (6e-10,18660810)
chr9	12288919	12470001	181083	rs13289810	1e-19	Hair color	rs13289810 (1e-19,22556244)
chr9	12943001	13024001	81001	rs1360517	3e-06	AIDS	rs1360517 (3e-06,19754311)
chr9	16363001	16398278	35278	rs9406636;rs7864648	2e-08	Metabolite levels (Dihydroxy docosatrienoic acid);Height	rs9406636 (9e-07,23934736);rs7864648 (2e-08,20881960)
chr9	20096001	20177001	81001	rs16937883	7e-06	Asthma (toluene diisocyanate-induced)	rs16937883 (7e-06,19187332)
chr9	22125001	22142001	17001	rs1333049 ;rs1333049;rs10811661;rs2383208;rs7018475;rs1333051;rs10965250;rs7020996	1e-59	Coronary artery disease;Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;Type 2 diabetes;Fasting glucose-related traits (interaction with BMI);Coronary artery calcification;Coronary heart disease	rs1333049  (3e-56,24262325);rs1333049 (1e-56,24262325);rs1333049 (1e-59,24262325);rs10811661 (1e-18,23945395);rs2383208 (3e-06,23209189);rs2383208 (3e-17,22961080);rs10811661 (7e-06,22581228);rs7018475 (3e-08,22293688);rs1333049 (3e-24,22144573);rs1333049 (7e-58,21606135);rs1333051 (6e-10,21573907);rs10965250 (1e-10,20581827);rs2383208 (2e-29,19401414);rs10811661 (7e-07,19056611);rs7020996 (2e-07,18372903);rs1333049 (3e-19,17634449);rs1333049 (1e-13,17554300);rs10811661 (5e-08,17463246);rs10811661 (8e-15,17463248);rs10811661 (5e-06,17463249)
chr9	22332001	22374001	42001	rs961831	7e-06	Personality dimensions	rs961831 (7e-06,20691247)
chr9	22594001	22913001	319001	rs7849973;rs12554707;rs10811771;rs613391	8e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Response to amphetamines;Response to antipsychotic therapy (extrapyramidal side effects);Quantitative traits	rs7849973 (8e-06,23453885);rs12554707 (2e-06,22952603);rs10811771 (8e-07,19875103);rs613391 (5e-06,19197348)
chr9	24069001	24156001	87001	rs4246856;rs2225614	3e-06	D-dimer levels;Quantitative traits	rs4246856 (6e-06,21502573);rs2225614 (3e-06,19197348)
chr9	25426001	25482001	56001	rs12552736;rs13300284	2e-06	RR interval (heart rate)	rs12552736 (2e-06,20031603);rs13300284 (4e-06,20031603)
chr9	28400001	28434180	34180	rs10968576;rs1412239;rs10968562	3e-13	Obesity;Obesity-related traits;Body mass index	rs10968576 (3e-08,23563607);rs1412239 (2e-10,23563607);rs10968562 (7e-06,23251661);rs10968576 (3e-13,20935630)
chr9	76104181	76180181	76001	rs12555078;rs11143609	2e-06	Obesity-related traits;HIV-1 control	rs12555078 (2e-06,23251661);rs11143609 (7e-06,20041166)
chr9	81833181	81997181	164001	rs13292136;rs2769967	3e-08	Type 2 diabetes;Inattentive symptoms	rs13292136 (3e-08,20581827);rs2769967 (3e-06,18821565)
chr9	82774181	83177181	403001	rs12554086	4e-07	RR interval (heart rate)	rs12554086 (4e-07,20031603)
chr9	90799447	90875878	76432	rs2778031;rs2814828	9e-13	Height	rs2778031 (9e-13,20881960);rs2814828 (9e-07,18391951)
chr9	92224181	92297181	73001	rs10908907	6e-06	Alcoholism (heaviness of drinking)	rs10908907 (6e-06,21529783)
chr9	100524321	100591462	67142	rs965513;rs1443438;rs925489;rs7850258	2e-27	Thyroid cancer;Obesity-related traits;Hypothyroidism;Thyroid cancer (Papillary, radiation-related)	rs965513 (3e-10,23894154);rs1443438 (1e-09,23251661);rs925489 (2e-19,22493691);rs7850258 (4e-09,21981779);rs965513 (5e-12,20350937);rs965513 (2e-27,19198613)
chr9	104531180	104698180	167001	rs4523321;rs10989661	1e-06	Obesity-related traits;Smoking behavior	rs4523321 (1e-06,23251661);rs4523321 (2e-06,23251661);rs10989661 (6e-06,19247474)
chr9	108832446	109133240	300795	rs2090409;rs7861820	2e-33	Pubertal anthropometrics;Menarche (age at onset);Menarche and menopause (age at onset)	rs2090409 (2e-06,23449627);rs2090409 (2e-33,21102462);rs7861820 (3e-09,19448621);rs2090409 (2e-09,19448620)
chr9	110876446	110943446	67001	rs865686	1e-34	Breast cancer	rs865686 (1e-34,23535729);rs865686 (2e-10,21263130)
chr9	120996180	121121180	125001	rs876347	2e-06	Response to antipsychotic therapy (extrapyramidal side effects)	rs876347 (2e-06,19875103)
chr9	121319447	121368447	49001	rs11789399;rs1572299	6e-09	Bipolar disorder and schizophrenia;Schizophrenia	rs11789399 (6e-09,20889312);rs1572299 (4e-06,19571808)
